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Sommario 
Streptococcus pneumoniae (S. pneumoniae) è uno tra i più importanti batteri 
patogeni per l’uomo se si considerano il tasso di mortalità e morbilità ad esso 
associati su scala mondiale (circa un milione e mezzo di morti ogni anno tra i bambini 
di età inferiore a 5 anni). S. pneumoniae è in grado di causare diverse malattie, sia 
non invasive che invasive, quali otite media, polmonite, sepsi e meningite, ma è 
anche annoverato tra i patogeni umani in grado di colonizzare asintomaticamente il 
tratto respiratorio di bambini e adulti sani. La colonizzazione è una fase necessaria 
per lo sviluppo di un'infezione respiratoria o sistemica ed è, infatti, un passaggio 
obbligato per il contagio nella comunità. I gruppi più a rischio d’infezione sono 
neonati, bambini al di sotto dei 5 anni di età, anziani ed individui 
immunocompromessi o immunodeficienti. Attualmente circa un milione di decessi 
l'anno vengono attribuiti ad infezioni da pneumoccocco e, di queste, il 50% circa 
coinvolgono bambini al di sotto dei 3 anni, o anziani affetti da polmonite. Il fallimento 
di trattamenti terapeutici antibiotici dovuto alla rapida diffusione di cloni contenenti 
elementi che conferiscono resistenza agli antibiotici anche di ultima generazione 
(quali i macrolidi), ha fatto sì che un enorme sforzo della comunità scientifica fosse 
diretto allo sviluppo di un vaccino in grado di prevenire l’insorgenza di patologie 
associate a  S. pneumoniae.  
S. pneumoniae è un batterio Gram-positivo caratterizzato dalla presenza sulla sua 
superficie di una spessa capsula polisaccaridica, considerata uno dei suoi principali 
fattori di virulenza. La capsula è, infatti, altamente immunogenica e in grado di 
indurre un aumento dell’invasività dello pneumococco favorendone la capacità di 
eludere i meccanismi di difesa aspecifici dell'ospite, primo tra tutti la fagocitosi. Ad 
oggi sono noti 94 sierotipi polisaccaridici capsulari differenti, identificati in base alle 
caratteristiche antigeniche del polisaccaride capsulare. Recenti studi di 
epidemiologia molecolare condotti in diverse regioni hanno dimostrato che i sierotipi 
capsulari hanno una distribuzione diversa a seconda della regione e che esiste una 
correlazione tra il sierotipo ed il grado di patogenicità. Inoltre, la presenza in individui 
sani di anticorpi specifici contro certi polisaccaridi capsulari garantisce la protezione 
in questi individui da infezioni causate da sierotipi omologhi.  
Le precedenti osservazioni giustificano che tutti i vaccini attualmente in commercio 
siano a base polisaccaridica. In particolare, esistono vaccini polisaccaridici 
(Pneumovax 23) e polisaccaridici coniugati (Prevenar7, Prevenar13, Synflorix), tutti 
contenenti un numero limitato di sierotipi capsulari e in grado di indurre un’immunità 
sierotipo-specifica. Solo i vaccini a base di glicoconiugati sono immunogenici nei 
bambini al di sotto dei 2 anni di età, che, come detto precedentemente, costituiscono 
una delle maggiori categorie a rischio. Sebbene questi vaccini abbiano dimostrato 
una buona efficacia nel ridurre i casi di malattia invasiva causata da S. pneumoniae, 
il loro uso è limitato dal fatto che inducono un’immunità sierotipo-specifica e pertanto 
sono in grado di proteggere efficacemente solo contro le malattie invasive causate 
dai sierotipi contenuti nel vaccino stesso. Questo implica che, in base alla diversa 
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distribuzione dei sierotipi, i vaccini polisaccaridici in commercio possono avere un 
grado di copertura diverso a seconda della regione esaminata. Inoltre, la 
vaccinazione di massa in alcuni stati ha indotto una ridistribuzione dei sierotipi 
circolanti. Questo fenomeno, noto come “serotype replacement”, consiste nello 
spiazzamento dei sierotipi contenuti nel vaccino da parte di altri non contenuti nel 
vaccino (non-vaccine types) e si pensa possa essere responsabile di una futura 
diminuzione della copertura garantita dai vaccini tuttora in commercio. 
Per queste ragioni, il mondo della ricerca si è indirizzato verso lo sviluppo di un 
vaccino su base proteica che possa indurre una protezione sierotipo-indipendente 
contro l’infezione pneumococcica.  
Un aspetto dibattuto della vaccinazione anti-pneumococco s’incentra sulla necessità 
che il vaccino debba prevenire la colonizzazione oppure semplicemente la malattia 
invasiva; è comunque chiaro che un vaccino ideale dovrebbe essere specie-specifico 
ed efficace nei gruppi a rischio.  
L'identificazione di proteine immunogeniche conservate di pneumococco rappresenta 
quindi un passo cruciale. Infatti, le proteine identificate potrebbero essere utilizzate 
come proteine "carrier" in vaccini glicoconiugati, oppure come unici componenti di 
vaccini a base interamente proteica, se la protezione da esse fornita fosse adeguata. 
Questo ridurrebbe fortemente i costi di produzione, e renderebbe praticabile la 
distribuzione del vaccino anche nei paesi in via di sviluppo.  
Tra le proteine selezionate nel corso degli anni come potenziali componenti di un 
vaccino vi sono la pneumolisina, PspA, PsaA, CbpA. Alla lista delle proteine 
storicamente già identificate come importanti antigeni recentemente si sono aggiunte 
le subunità proteiche che costituiscono il pilo-1, una struttura fibrillare identificata 
sulla superficie di alcuni ceppi di S. pneumoniae.  
Come accade in molti altri batteri della specie streptococco, la superficie di S. 
pneumoniae è decorata da pili con caratteristiche adesive, composti da subunità 
legate covalentemente, importanti per la virulenza ed in particolare per l’adesione 
iniziale dei batteri alle cellule epiteliali.  
In particolare, i pili dello pneumococco sono codificati da due regioni nel genoma 
denominate pilus islet-1 (PI-1) e pilus islet-2 (PI-2), presenti rispettivamente circa nel 
30% e nel 16% dei ceppi di pneumococco circolanti. Sono note tre varianti di PI-1, 
clonalmente correlate, mentre esiste una sola variante di PI-2. La presenza delle due 
isole non correla con il sierotipo dei batteri, ma con il loro genotipo determinato 
tramite Multi Locus Sequence Typing (MLST). La prevalenza di ceppi positivi per la 
presenza di PI-1 o PI-2 è simile in isolati derivanti da malattie invasive o da carriage, 
mentre la prevalenza di ceppi positivi per PI-1 è più elevata in collezioni di ceppi 
antibiotico-resistenti, dove raggiunge anche il 60%. Quest’ultima osservazione 
favorisce l’ipotesi che, da un lato i batteri PI-1 positivi possano acquisire più 
8 
 
facilmente determinanti di resistenza, e, dall’altro, che l’espressione del pilo-1 possa 
costituire essa stessa un  fattore di vantaggio per la diffusione della malattia.  
Diversi studi hanno dimostrato che le subunità del pilo-1 (RrgA, RrgB ed RrgC) 
conferiscono un altissimo grado di protezione in modelli murini di infezione sia in 
esperimenti di immunizzazione attiva che passiva. Per questo motivo, nonostante il 
pilo-1 non sia presente in tutta la popolazione batterica e le sue subunità costituenti 
non siano altamente conservate,  RrgA, RrgB ed RrgC sono considerati potenziali 
candidati per essere inseriti in un vaccino a base proteica di nuova generazione. 
RrgB in particolare, oltre ad essere la subunità più abbondante del pilo, essendo il 
costituente dello scheletro, è anche la più protettiva.  
 
È nel contesto della caratterizzazione di fattori di virulenza di S. pneumoniae che si 
inserisce il mio lavoro di ricerca, incentratosi principalmente su due progetti, che 
mirano a: 1) definire se esiste un’ associazione tra la presenza dell’ isola codificante 
per il pilo-1 (PI-1) e frequenza di trasmissione di S. pneumonie e/o la durata della 
colonizzazione; 2) evidenziare il meccanismo molecolare associato all’inusuale 
assenza di espressione della capsula in ceppi isolati da malattia invasiva. 
 
1. Assessment of Streptococcus pneumoniae PI-1 prevalence in carried and 
transmitted isolates from, mother-infant pairs on the Thailand-Burma border. 
 
Dal momento che le proteine costituenti il pilo sono considerate potenziali candidate 
per un vaccino a base proteica contro lo Streptococcus pneumoniae e che il pilo-1 è 
considerato uno dei fattori importanti nell’iniziale adesione dello pneumococco alla 
cellula ospite durante la colonizzazione, lo scopo di questo lavoro è stato quello di 
valutare la prevalenza dell’isola del pilo-1 (PI-1) in una collezione di ceppi isolati da 
carriage durante uno studio longitudinale e di valutare la possibile associazione tra la 
presenza dell’isola stessa e la colonizzazione dell’ospite (valutata da parametri quali 
durata di colonizzazione e probabilità di trasmissione madre-figlio). 
Lo studio ha previsto la caratterizzazione di ceppi colonizzatori del tratto 
nasofaringeo isolati tra il 2007 e il 2010 da 234 coppie di madri-bambini residenti 
nella zona di confine tra la Tailandia e la Birmania (zona in cui non è stato fino ad ora 
distribuito un vaccino contro lo pneumococco). Prelievi mensili alle madri e ai loro 
neonati, a partire dal primo mese di vita fino al compimento di un anno di età, hanno  
permesso di  isolare 2496  ceppi di Streptococcus pneumoniae. Tutti i ceppi isolati 
sono stati sierotipizzati e si è ipotizzato che la presenza di uno stesso sierotipo in 
mesi successivi corrispondesse ad un singolo episodio di colonizzazione. Un 
sottogruppo di questi isolati (896) è stato poi scelto per essere rappresentativo degli 
episodi di colonizzazione e di trasmissione tra madre e figlio verificatisi durante il 
periodo di osservazione e i cui criteri di definizione sono stati stabiliti all’interno dello 
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studio. Questi isolati, rappresentativi di 34 sierotipi, sono stati caratterizzati dal punto 
di vista genotipico mediante MLST (Multi Locus Sequence Typing) e la presenza di 
PI-1 valutata tramite PCR. La procedura MLST prevede l’amplificazione e il 
sequenziamento di 7 frammenti appartenenti a 7 geni costitutivamente espressi di 
pneumococco. La determinazione della loro sequenza consente l’assegnazione di un 
numero di allele per ogni gene, mentre la combinazione dei 7 alleli permette la 
determinazione univoca di un numero, denominato Sequence Type (ST). 
Degli 896 ceppi analizzati per 887 è stata determinata con successo la positività per 
PI-1 che è risultata essere pari al 35.2% (312/887). In particolare, PI-1 è associata 
soltanto a 10 dei 34 sierotipi (in misura maggiore ai sierotipi 19F e 23F) a cui 
appartengono i ceppi analizzati. 
Un’analisi più dettagliata ha permesso poi di valutare la possibile associazione tra la 
presenza e/o assenza di PI-1 e la trasmissione del patogeno tra madri e rispettivi 
figli. Un pannello ristretto di ceppi (483 isolati), comprendenti sia isolati trasmessi che 
non trasmessi è stato selezionato per tale scopo (l’effettiva presenza di casi di 
trasmissione è stata determinata dalla concordanza di sierotipo e ST in ceppi isolati 
da coppie madre-figlio). In particolare, nell’analisi sono stai inclusi i ceppi 
appartenenti ai sierotipi presenti nel vaccino tredici-valente (Prevnar-13) e i ceppi 
non sierotipizzabili, che costituiscono una frazione molto abbondante dell’intera 
collezione. 
Dei 483 ceppi analizzati, 219 sono risultati essere positivi per la presenza di PI-1 
(45.3%) con una frequenza molto più elevata per sierotipi come 19F e 23F dove la 
presenza dell’isola è stata trovata rispettivamente nel 91% e nel 77% dei ceppi. 
L’associazione tra sierotipo e presenza del pilo osservata in questo studio va 
ricercata soprattutto nel genotipo di appartenenza dei ceppi analizzati e può essere 
spiegata con la differente diffusione regionale che molto spesso si osserva per 
infezioni/colonizzazioni da parte dello pneumococco; inoltre, tale associazione può 
dipendere dai criteri di selezione applicati allo studio. 
L’analisi della trasmissibilità dei ceppi tra madri e rispettivi neonati non ha 
evidenziato alcuna correlazione tra la presenza dell’isola del pilo e la trasmissione 
del ceppo di S. pneumoniae. Infatti, non c’è differenza statisticamente significativa tra 
la prevalenza di PI-1 in ceppi trasmessi (47.5%) tra madre e figlio rispetto a quelli 
non trasmessi (43.3%) (OR1.2; 95% CI: 0.8: p=0.4). 
Inoltre, per quanto riguarda l’analisi dell’associazione tra la presenza di PI-1 e la 
durata del periodo di colonizzazione, gli episodi di carriage sono risultati essere 
complessivamente più lunghi per gli isolati PI-1 positivi. Tuttavia, questo dato perde 
di significatività statistica effettuando l’analisi tenendo conto di un elemento 
confondente quale il sierotipo (essendo noto che tipi capsulari diversi sono associati 
a durate di carriage diverse, visto il piccolo numero di  isolati analizzati e 
l’associazione PI-1/clone/sierotipo).  
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In conclusione, la collezione analizzata, pur provenendo da un’area geografica (Sud-
est Asia) epidemiologicamente ancora non ben caratterizzata, presenta una 
prevalenza di ceppi PI-1 positivi in linea con precedenti studi epidemiologici. Inoltre, 
l’analisi della collezione non ha evidenziato particolari associazioni tra la presenza di 
PI-1 e la trasmissibilità e/o la durata temporale del carriage. 
 
1. Point mutations in wchA are responsible for non-typeability of two invasive 
Streptococcus pneumoniae isolates. 
La capsula polisaccaridica è uno dei fattori di virulenza più importanti per lo 
pneumococco e la sua espressione è strettamente associata all’invasività. La 
capsula conferisce infatti agli streptococchi una maggiore resistenza alla fagocitosi 
mediata dalle cellule dell’ospite e garantisce quindi la sua persistenza in distretti quali 
l’apparato circolatorio.  
Sebbene, come precedentemente indicato, gli isolati di S. pneumoniae presentino 
generalmente una capsula sulla loro superficie, esiste una piccola percentuale di 
ceppi di S. pneumoniae, che non presenta una reazione positiva con nessuno dei 
sieri usati per la tipizzazione. I ceppi di questa sotto-categoria sono stati definiti Non-
Typeable (cioè non tipizzabili, NT). I ceppi NT o sono acapsulati o esprimono una 
quantità di capsula molto limitata, non sufficiente per essere evidenziata con le 
tradizionali tecniche di rilevamento. Per questo motivo, i ceppi NT sono isolati quasi 
esclusivamente da episodi (epidemie) di congiuntivite o da tamponi naso-faringei e 
sono ritrovati solo molto raramente in isolamenti effettuati da infezioni invasive dove 
l’assenza della capsula rende la loro persistenza piuttosto improbabile.   
Le basi genetiche della non tipizzazione, che alterano l’espressione di una o più 
proteine del locus capsulare, sono state studiate in generale solo per collezioni 
piccole e scarsamente rappresentative e in generale per ceppi NT isolati da casi di 
colonizzazione o congiuntivite. I meccanismi molecolari evidenziati finora come 
responsabili della non tipizzazione sono la perdita di parte o dell’intero locus 
capsulare (contenente i geni che codificano per le proteine responsabili 
dell’assemblaggio dei polisaccaridi), l’inserzione di geni, mutazioni puntiformi o 
duplicazioni di sequenza. 
 L’analisi genetica di ceppi NT (tramite tipizzazione MLST, vedi capitolo 1) ha 
evidenziato che essi possono appartenere a cloni tipicamente associati a NT 
pneumococci o, più raramente, a cloni generalmente associati a sierotipi. 
Visto le sopra elencate premesse, l’isolamento nel 2006 di ceppi NT da due casi di 
polmonite bacteriemica nello stesso ospedale italiano è stato considerato un evento 
raro. Per questo motivo si è deciso di procedere alla caratterizzazione genetica della 
loro non-tipizzabilità.  
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La genotipizzazione dei due isolati tramite MLST ha evidenziato che entrambi 
appartengono all’ST191 che è generalmente associato al sierotipo 7F. 
Successivamente, il sequenziamento dell’intero locus capsulare dei due ceppi non-
tipizzabili ha confermato la presenza dell’intero locus capsulare di tipo 7F. Un’analisi 
dettagliata della sequenza ha consentito di evidenziare in ognuno dei due ceppi la 
presenza di una mutazione puntiforme nel gene wchA (mutazioni diverse nei due 
ceppi), codificante per la proteina glicosiltransferasi che, in generale, è responsabile 
del primo passaggio di assemblaggio del polisaccaride. Entrambe le mutazioni 
comportano la traduzione di una proteina WchA tronca all’estremità C-terminale, che 
risulta probabilmente non funzionale.  
Al fine, poi, di verificare l’effettiva responsabilità delle due mutazioni presenti nel 
gene wchA della non-tipizzabilità dei ceppi testati, si sono trasformati entrambi gli 
isolati non-tipizzabili con un plasmide pMU1328 contenente un gene 7F wchA 
codificante per una proteina WchA funzionale.  
I due ceppi over-esprimenti WchA e i due ceppi non-tipizzabili sono stati analizzati 
mediante spettroscopia NMR e microscopia elettronica al fine di verificarne il fenotipo 
e misurare lo spessore di un’eventuale capsula presente sulla superficie batterica. E’ 
stata confermata l’assenza di una capsula polisaccaridica sulla superficie dei ceppi 
non-tipizzabili, mentre il ripristino di WchA è stato sufficiente a riattivare il normale 
assemblaggio di una capsula 7F in entrambi i ceppi NT.  
In conclusione, in questo studio si sono identificate due nuove mutazioni puntiformi 
spontanee responsabili della non-tipizzabilità di pneumococco e si è inoltre 
dimostrato che WchA è essenziale per una corretta biosintesi del tipo capsulare 7F. 
Tuttavia, assunto che i due NTPn analizzati non sono in grado di assemblare una 
capsula a causa di una mutazione puntiforme incorsa in un gene essenziale, resta da 
chiarire come i due ceppi siano riusciti a causare una malattia invasiva. La mancanza 
di dati clinici riguardo ai pazienti non ha permesso la formulazione di una teoria a tale 
proposito. 
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Introduction 
1. A brief history of vaccines. 
 
Vaccines in the era of genomics. 
 
Vaccination, together with the wider availability of potable water, has had the 
most profound positive effect on the quality of the public health. During the past 
century, vaccination essentially eliminated many infectious diseases causing 
mortality in infants and in children. Less than two hundred years ago life expectancy 
was around 40 years of age, a condition that still persists in some undeveloped 
countries. From about the middle of the nineteenth century, great improvements in 
living standards were made in industrialized countries, initially by providing adequate 
sanitation facilities and safe drinking water. However, this was not enough to prevent 
epidemics and sometimes pandemics of infectious diseases. In fact, the “Spanish flu” 
in 1918-19 killed over 30 million people, more than all those who died in World War I 
during 1914-1918; and Smallpox was a terrible killer for centuries, responsible for 
many millions of victims. Coping with these issues became progressively possible 
only through the development of vaccines against some of the major diseases.  
Vaccines against diphtheria, tetanus, polio, measles, mumps, rubella, 
pneumococcus, hepatitis B and meningitis have reduced the incidence and mortality 
of these diseases by > 97-99% (Rappuoli et al., 2002). Nevertheless, perception of 
vaccines in the public opinion is not completely positive. A lot of people are still 
skeptical about the real need of vaccines, and this attitude has been particularly 
evident during the influenza A (H1N1) pandemic in 2009. Indeed, persons tend not to 
realize the importance of illness prevention, if the disease is not causing the death of 
the patients. Novel vaccines in fact do not only prevent deaths directly caused by 
pathogens but can also prevent malignancies associated with them (e.g. 
papillomavirus, hepatitis B virus and Helicobacter pylori). Prevention of infections can 
increase patient fitness (by decreasing the number of infectious episodes and 
associated sequelae), and, reducing the number of harmful inflammatory processes 
happening during infections, prolong life expectancy (Crimmins and Finch, 2006). In 
addition, the socio-economic costs of hospitalizations and the positive effects 
associated with extensive vaccination programs, like the overall reduction of the 
incidence of infections (herd immunity) and the reduced use of antibiotics and 
antivirals (decreasing the emergence of resistances), are not always duly taken into 
account.  
Infectious diseases, despite antimicrobial therapies, remain the leading cause of 
death worldwide. In addition, infectious diseases for which a cure is not available or 
not efficacious are expected to emerge (or re-emerge) in the coming decades. 
Therefore, the development of novel vaccines against these diseases is mandatory 
(Jones et al., 2008; Rappuoli, 2004).  
The majority of the vaccines available to date (e.g. polio, smallpox, pertussis and 
tetanus) were developed using conventional vaccinology strategies based on the 
Pasteur’s principle of “isolate, inactivate and inject” (Rappuoli 2004; Robbins et al., 
2005). Although very successful, this approach failed against certain pathogens and, 
in other occasions, the obtained vaccines are no longer adequate due to safety 
concerns and low efficacy.  
In detail, the conventional approach has been always successful in developing 
vaccines against pathogens that do not change the vaccine-targeted antigens over 
time (and with an overall low degree of species variability) and for which protection is 
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antibody-mediated (Rappuoli, 2007). However, it has been also successful in 
targeting particular pathogens displaying many variants of target-vaccine antigens. 
Examples of such vaccines are the ones based on polysaccharide antigens of 
pneumococcus and meningococcus. On the other hand, as already mentioned 
above, for certain pathogens the conventional vaccine development approach has 
failed. The reasons for these failures have been probably the high antigen variability 
and the fact that protection is mediated by mechanisms which are still not clearly 
understood. For all these cases, a huge investment to implement new methods for 
novel vaccine candidate discovery and to develop new technologies to express, 
deliver and formulate antigens, is necessary.  
 
 
A modern vaccine design: The Reverse Vaccinology. 
 
In the last two decades, important discoveries have enlightened the science of 
molecular immunology, proteomics, physicochemestry, genomics, and systems 
biology. These advances have totally changed the way vaccines are designed, 
characterized and developed.  
Genome sequencing has become routine, and modern vaccine design is taking 
advantage of the accumulating genomic information, revolutionizing the study of 
microbial pathogenesis, genetics and population biology. The alliance between 
technological innovations, such as high-throughput sequencing, coupled with reverse 
genomics and conventional vaccinology has led to a new paradigm of vaccine 
development (Scarselli et al., 2005). 
In the year 2000, a revolutionary approach to identify and develop new vaccines was 
published (Pizza et al., 2000). The strategy was called reverse vaccinology (RV), 
since the initial identification of vaccine candidates was not performed based on 
experimental observations but on a bioinformatic analysis of the pathogens’ genome. 
In detail, RV is based on a “multiple antigen selection approach” comprising in silico 
antigen prediction, functional genomics and comparative genomics; the final 
identification of the vaccine candidates is then based on epidemiological data 
(conservation and expression of the antigens) and immunogenicity/protection 
screenings, performed with animal model experiments, human sera analysis, and 
expression libraries screenings (Fig. 1).  
 
This approach has largely replaced classical vaccinology methods. Its main 
advantage is the fast in silico prediction of vaccine candidates, which will mainly be 
surface exposed proteins, most likely accessible to antibodies binding during 
infection (Rappuoli, 2004). Interestingly, another advantage of this approach is that it 
could be applied to non-cultivable microorganism, difficult or impossible to target with 
conventional approaches. 
The RV methodology has been initially applied on the serogroup B Neisseria 
meningitidis (MenB). The project served as proof of concept of the validity of the 
method and led to the development of a multivalent recombinant vaccine that is now 
in phase III clinical trials. The MenB project demonstrated the strength, the speed 
and all the advantages of the RV over classical vaccine approaches.  
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Fig. 1: The complete reverse vaccinology process. Reverse vaccinology starts with antigen 
prediction based on in silico analysis as well as comparative genomics and functional genomics. The 
availability of genomes and bioinformatic tools is essential to the in silico prediction of all potential 
open reading frames (ORFs) as well as comparative and functional genomics and proteomics. During 
the next phase, the antigens are purified and screened for protection efficacy, epidemiological 
relevance, expression profile, immunoreactivity against human sera. They are also characterized for 
their function and toxicity. Ideally, a vaccine should consist of one to five different antigens. 
 
 
2. Epidemiological studies: aims and relevance. 
 
Definition and objectives of Epidemiology. 
 
Epidemiology is the study of how disease is distributed in populations and of the 
factors that influence or determine this distribution. Why does a disease develop in 
some people and not in others? The premise underlying epidemiology is that 
disease, illness, and ill health are not randomly distributed in a population. Rather, 
each of us has certain characteristics that predispose to, or protect against, a variety 
of different diseases. These characteristics may be primarily genetic or the result of 
exposures to certain environmental hazards (Fig. 2).  
 
More broadly epidemiology is defined as: 
 
“The study of the distribution and determinants of health-related states or events in a 
specified population and the application of this study to control of health problems” 
(Last JM: A dictionary of Epidemiology, ed. 2 New York, Oxford University Press, 
1988) 
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Noteworthy, this definition incorporates both a description of the content of the 
discipline and the purpose or application for which epidemiologic investigations are 
carried out. 
 
                          
                 
 
Fig. 2: The epidemiologic triad of a disease. According to the diagram, a disease is the product of 
an interaction of the human host, an infectious or other type of agent and the environment that 
promotes the exposure. 
 
 
What are the specific objectives of epidemiology? 
 
First, to identify the etiology or the cause of a disease and the risk factors-that is, 
factors that increase a person’s risk for a disease.  
 
It is important to understand how the disease is transmitted from one person to 
another or from a non-human reservoir to a human population. The ultimate aim is, in 
fact, to intervene to reduce morbidity and mortality caused by the disease. The 
identification of the etiologic or causal factors of the disease and the reduction or 
elimination of the exposure to those factors, are the basis for the development of 
rationally designed prevention programs. 
 
Second, to determine the extent of disease found in the community. 
 
What is the burden of disease in the community? This question is critical for planning 
health services and facilities and for training future health care providers.  
 
Third, to study the natural history and prognosis of disease.   
 
Clearly, certain diseases are more severe than others; some may be rapidly lethal, 
and others may have longer or shorter durations of survival. The baseline natural 
history of a disease has to be defined in quantitative terms to develop new modes of 
intervention, either through treatments or new ways of preventing complications. 
 
Fourth, to evaluate new preventive and therapeutic measures and new modes of 
health care delivery.  
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The development of effective vaccines specifically targeting the major invasive 
pathogens represents a significant advance in improving the public health.  
 
Fifth, to provide the foundation for developing public policy and regulatory decisions 
related to environmental problems.  
 
 
The Molecular Epidemiology of infectious disease: a simple extension of the 
Epidemiology definition. 
 
 
Epidemiology, as said before, is often defined as:  
 
“the study of the distribution and determinants of diseases and injuries in human 
populations” (Mausner et al., 1974).  
 
A simple extension of this definition to molecular epidemiology of infectious diseases 
is:  
 
“the study of the distribution and determinants of infectious diseases that utilizes 
molecular biology methods.”  
 
As early as 1977, Higginson defined molecular epidemiology as: 
 
“the application of sophisticated techniques to the epidemiologic study of biological 
material” (Higginson, 1977).  
 
More recently, Levin et al. stated:  
 
“The practical goals of molecular epidemiology are to identify the microparasites 
responsible for infectious diseases and determine their physical sources, their 
biological relationships, and their route of transmission and those of the genes 
responsible for their virulence, vaccine-relevant antigens and drug resistance” (Levin 
et al., 1999).  
 
In general, the word “determinants” in the definition of epidemiology is 
emphasized, as the main goal of nearly all molecular epidemiologic studies is the 
characterization of determinants of disease distribution.  
It is recognized that infectious disease distribution and determinants of this 
distribution may be identified by molecular biology techniques; it is also becoming 
evident that infectious disease distribution in a community of hosts may itself be 
determined or “programmed” by a pathogen’s own genetic material that evolved in 
response to hosts’ antimicrobial machinery as well as to the environment in which the 
pathogen resides. That is, every human, animal, and plant pathogen has evolved to 
transmit itself to a host or to a community of hosts in its own characteristic fashion 
within a specific environmental context. Mechanisms that underlie an organism’s 
specific pattern of transmission may, thus, be genetically and environmentally 
determined. The discipline of molecular epidemiology, therefore, should also include 
the study of genetic factors that determine and regulate an organism’s specific 
pattern of transmission. 
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The relevance of Epidemiological Studies. 
 
In recent years, epidemiology has become an essential approach in both health 
and clinical practice, while prevention and therapy are still too often viewed as 
mutually exclusive activities. In fact, this discipline is the basic science for the 
development of disease prevention strategies, playing major roles in the 
development and evaluation of public health policies. Epidemiology is used together 
with laboratory research to identify risk factors for disease and to shed light on the 
mechanisms involved in pathogenesis. Indeed, epidemiologic studies play a 
fundamental role in the entire process of drug or vaccine development during all of 
the phases: pre-clinical, clinical and post-market.  
Actually, one of the main objectives of the public health community consists in the 
reduction of infectious disease burden due to different invasive pathogens, among 
which the pneumococcus is one of the most important. In fact, Streptococcus 
pneumoniae causes high morbidity and mortality throughout the world (even in 
regions where antibiotics are readily available) and, together with HIV, malaria, and 
tubercolosis, it represents one of the four major infectious disease killers. 
 
 
3. Streptococcus pneumoniae. 
 
Pathogenesis of pneumococcal disease: colonization and invasion. 
The Gram-positive bacterium Streptococcus pneumonia (S. pneumoniae), also called 
pneumococcus, was first isolated by Pasteur in 1881 from the saliva of a patient with 
rabies. Typically, it is observed in pairs (diplococci) but sometimes also single 
bacteria or in short chains (Fig. 3).  
 
                   
Fig. 3:  General representation of the bacterium Streptococcus pneumoniae. 
    
S. pneumoniae bacteria are part of the human nasopharyngeal commensal flora but 
are also able to cause a variety of illnesses, which include invasive pneumococcal 
diseases (IPDs) such as bacteremia, meningitis and bacteremic pneumonia. 
Furthermore, pneumococci are a common cause of mucosal infections such as otitis 
media, sinusitis, mastoiditis and non-bacteremic pneumonia (Rose et al., 2009) (Fig. 
4).  
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Colonization is commonly followed by horizontal dissemination of the pathogens to 
individuals in the direct environment, thus leading to spread within the community 
(Givon-Lavi et al., 2002). The reported rates of bacterial acquisition and carriage 
depend on age, geographical area, genetic background, and socioeconomic 
conditions; risk groups for diseases caused by pneumococci include children under 
the age of 2 years, elderly and patients with immunodeficiencies. S. pneumoniae 
colonization is a dynamic process; indeed, the competition with the resident flora for 
the persistence in the human airways has an important role in determining the 
colonization rates of pneumococcus and other virulent microorganisms. Besides, also 
the efficiency of the local host immune response, strictly depending on the condition 
of the upper respiratory tract, has to be taken into account; in fact, a poor mucosal 
immune response can lead to persistent and recurrent colonization and consequent 
dissemination of the infection, whereas a brisk local immune response to the 
pathogen can eliminate colonization and prevent re-colonization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
                
 
 
Fig. 4: Diagram of the different pneumococcal diseases correlating with the probability of 
microbiology diagnosis. For example, it’s very hard to recover samples of the s pneumonia strains 
that cause bacteremic pneumoniae. 
 
 
This re-colonization process is very common, and, in fact, probably all humans are 
colonized with this organism at least once early in their life. Especially in crowded 
environments, such as day-care centers, nursing homes, hospitals and jails, the risk 
of colonization is extremely high. As already mentioned before, colonization is not 
usually followed by disease, since this is prevented by the innate and adaptive 
immune system. However, disturbance of homeostasis between host and pathogen, 
for example through viral infections, malnutrition or local damage of the mucosa, is 
associated with an increased development of pneumococcal (invasive) diseases.  
It is generally accepted that Streptococcus pneumoniae infection can progress to 
respiratory or even systemic disease following the initial, mostly symptomless, 
colonization of the nasopharynx (Bogaert et al., 2004). However, despite the high 
burden of disease, the pathogenic mechanisms exploited by S. pneumoniae to 
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adhere to human epithelia, most likely triggering the colonization process, and to 
then progress to invasive disease are still poorly understood.  
A major virulence factor of Streptococcus pneumoniae is the polysaccharide capsule. 
The pneumococcal capsule displays an extremely high variability (it exists in fact in at 
least ninety different types, known as serotypes) and provides an effective barrier 
against host-cell mediated phagocytosis allowing bacterial persistence in the blood. 
In addition to the capsular determinant, many other secreted or surface exposed 
factors have been described to be of importance for virulence through in vivo animal 
model studies and in vitro experiments (i.e. choline-binding protein A (CbpA), the 
pneumococcal toxin pneumolysin, pilus components, pneumococcal surface protein 
A (PspA), pneumococcal surface adhesin A (PsaA), pilus components); however, 
their direct contribution to and essentiality for disease development in humans have 
still to be determined. 
 
 
Pneumococcal vaccines: polysaccharides and surface proteins 
 
Streptococcus pneumoniae-related infections have a major global impact on 
healthcare, especially in the developing world, and are considered the number one 
vaccine-preventable cause of death in children (Adam D., 2009). In fact, S. 
pneumoniae is the single commonest cause of community-acquired pneumonia, and 
has become the most frequent cause of meningitis in many regions. Although 
determining the exact burden of pneumococcal disease is complicated by difficulties 
in establishing an aetiological diagnosis, particularly in cases of non-bacteremic 
pneumonia, the pneumococcus is conservatively estimated to kill more than a million 
children under the age of 5 years each year in developing countries (Fig. 5). This 
accounts for 20-25% of all deaths in this age group (Williams et al., 2002; WHO, 
2007). Even in developed countries, where effective antimicrobial drugs are readily 
available, morbidity and mortality from pneumococcal disease is significant. The 
other major driver for vaccine development has been the increasing threat posed by 
antibiotic-resistant pneumococci. Since the discovery of the antibacterial properties of 
penicillin by Fleming in 1929, many antibiotics have been successfully used for 
treatment of pneumococcal infections. However, recently, antibiotic resistance has 
become a worldwide problem, limiting the choice of antimicrobial agents. Therefore, 
prevention of pneumococcal disease through vaccination has become of even 
greater interest. 
The increasing prevalence of penicillin- and multi-drug resistant pneumococci makes 
difficult the management of patients with suspected pneumococcal disease, 
particularly those with meningitis. In developed countries the problem is at a certain 
extent overcome by the use of more expensive alternative antimicrobials, but this 
option is not available in poorer parts of the world.  
All the vaccines that are currently present on the market are based on a limited 
number of pneumococcal capsular polysaccharides, conjugated or not to a carrier 
protein (from 7 to 13 different capsular types for the conjugated and 23 capsular 
polysaccharides for the unconjugated vaccines). These vaccines have all 
demonstrated good efficacy in reducing invasive disease caused by the serotypes 
included in the vaccines, and a limited efficacy against acute otitis media. In addition, 
the 7-valent, 10-valent and 13-valent conjugate vaccines, unlike the 23-valent 
polysaccharide non-conjugated vaccine, have proved good effectiveness in children 
under 2 years of age. However, due to the extremely high variability of the 
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pneumococcal capsule composition, and the different geographical distribution of the 
vaccine pneumococcal serotypes, the efficacy of these vaccines is mostly limited by 
their serotype-dependent coverage. In addition, following the vaccine introduction in 
the medical practice, epidemiological surveillance studies have reported an increase 
in the disease caused by non-vaccine types (known as serotype replacement 
events). 
 
 
     
 
 
Fig. 5: Graphic representation of pneumonia disease burden in children under the age of 5 
years each year, based on WHO estimates. 
 
 
Moreover, the prohibitive cost of producing conjugate vaccines is a limit for their use 
in developing countries with the highest burden of disease and poor economical 
resources. For these reasons, vaccine research is currently focusing toward the use 
of one or more universally conserved protein antigens as potential vaccine 
components, able to elicit serotype-independent protection (Ryan and Antonelli, 
2000). In this respect, cell-surface proteins, implicated in the interaction with host 
cells and tissues and playing an important role in pneumococcal virulence (Navarre 
and Schneewind, 1999), have attracted considerable attention and are currently 
under investigation as possible components of a multi-valent protein–based vaccine 
targeting pneumococcal disease (i.e. PcsB, PhtD, Stkp, PspA, RrgB pilus backbone, 
PspC, pneumolysin).  
Indeed, pneumococcal proteins can be exposed on the bacterial surface through 
different mechanisms; on this basis they can be distinguished in membrane 
(possessing one or more trans-membrane domains ), cell-wall anchored (linked to 
the cell-wall through an LPXTG motif), lipoproteins (covalently linked to a 
phospholipid) or choline binding (bound to choline residues decorating teichoic acid 
(TA) and lipoteichoic) acid proteins. 
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Fig. 6: Diagram of pneumococcal surface. Cell wall anchored proteins (CWAPs) are represented as 
well as some of the known virulence factor. 
 
Briefly, cell wall anchored proteins (CWAPs) are attached to the bacterial surface 
through a covalent linkage with the peptidoglycan (Fig. 6). Formation of this linkage is 
catalyzed by specialized membrane-associated transpeptidases known as sortases, 
which recognize the C-terminal LPxTG motif of proteins destined to be attached to 
the cell wall (Ton-That et al.,2004a). Immunoglobulin A1 protease, hyaluronidase and 
pilus components are examples of pneumococcal proteins known to be involved in 
bacterial virulence belonging to this category. Besides, S. pneumoniae is the only 
human-pathogenic bacterium thus far known to express surface proteins specifically 
binding to choline as a mechanism of surface attachment. Interestingly, several of the 
choline binding proteins (Cbps), like CbpA, CbpD, CbpE and CbpG as well as all 
three pneumococcal autolysins (LytA, LytB and LytC) and also PspA (all belonging to 
this category) are described as bacterial factors implicated in the colonization 
processes.  
 
  
Epidemiology of the pneumococcus: serotyping vs. molecular typing. 
 
 
More than 90 serotypes have been identified based on the antigenic composition of 
the polysaccharide capsule. All the serotypes exhibit a distinctive epidemiology with 
regard to their potential to cause invasive disease, their occurrence in specific age 
groups or geographic regions, their association with antibiotic resistance and their 
epidemic potential (Hausedorff et al., 2005), thus accounting for the serotype 
dependent vaccine coverage described above. Indeed, most S. pneumoniae 
serotypes have been associated at various degrees to invasive diseases, but, in 
each region, only few serotypes (and mainly region specific) account for the majority 
of pneumococcal infections, with serotype composition changing upon seasonal and 
epidemic variations due to different clones spread. Serotypes 1, 5, 6, 7, 14, 18, 19, 
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and 23 are the most prevalent worldwide, accounting for 60-80% of the invasive 
diseases, depending on the area of the world. On the other hand, the serotype 
distribution among nasopharyngeal carriage isolates varies considerably by country, 
age-group, and type of cohort analyzed.  
Capsular serotyping is currently the most widely used and efficacious strategy for 
classification of pneumococcal strains; however, this method presents some 
limitations like the inability to quantify the genetic relationship between isolates 
(population genetic) and the different accuracy in determining the serotypes achieved 
by different laboratories. In order to overcome these classification limits, a nucleotide 
sequence based method, Multi Locus Sequence Typing (MLST), has been 
developed with a global epidemiology perspective. This method involves the 
sequencing of internal fragments from seven house-keeping genes, and leads to the 
unequivocal assignment of the isolates to a sequence type (ST) (Chan et al., 2001). 
The strength of this approach is that sequence data are unambiguous, can be held 
on a central database (http://www.mlst.net) and be queried through a web server. On 
the other side, the expensiveness of this gene based strategy has strongly limited the 
diffusion of MLST typing to western rich countries. Interestingly, there is no univocal 
correspondence between the two classification methods, therefore, in defining an 
isolates both serotyping and MLST typing are needed, as serotypes are usually 
associated to more than an ST type and vice-versa. (Chan et al., 2001).  
Notably, the increased use of combined MLST and serotyping classifications has 
allowed following the spread through different regions and during time of specific 
clones, often “disguised” with different capsular serotypes. The genetic fitness 
factors, other than antibiotic resistance, responsible for the successful spread of 
these clones are currently under investigation. 
 
 
The pneumococcal capsule and its biosynthesis. 
 
As already mentioned above, the polysaccharide capsule is the most important 
virulence factor of the pneumococcus as it protects the bacteria from phagocytosis. 
Factor (typing) sera are used to divide pneumococci into serotypes and serogroups, 
which include immunologically related serotypes. At present, 92 individual serotypes 
are recognized by their patterns of reactivity with the factor sera (Bentley et al., 2006; 
Mavroidi et al., 2007a; Park et al., 2007), and serotypes vary in the extent to which 
they are carried in the nasopharynx and the degree to which they are recovered from 
different disease states (Hausdroff et al., 2000; Spratt et al., 2004). Expression of a 
capsule is important for survival in the blood and is strongly associated with the 
ability of pneumococci to cause invasive disease. The capsule is surface exposed, 
and antibodies against CPS provide a type-specific protection against pneumococcal 
disease. In detail, the capsule consists of high-molecular-weight polymers made up 
of units of repeated oligosaccharides (OS) which can contain between two and eight 
monosaccharides. Many serotypes possess acidic components (like D-glucuronic 
acid or phosphate groups), ribitol, or arabinitol (Van Dam et al., 1990). In six 
serotypes, phoshporylcholine (PC) is part of capsular PS (SØrensen et al., 1984). 
With the exception of types 3 and 37, which are synthesized by the synthase 
pathway (Llull et al., 1999; Cartee et al., 2001; Dillard et al., 1995; Arrecubieta et al., 
1994; Waite et al., 2003), pneumococcal CPSs are generally synthesized by the 
Wzx/Wzy-dependent pathway (Fig. 7). The genes for the latter pathway are located 
at the same chromosomal locus (cps), between dexB and aliA (Yother J., 2004; 
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Kolkman et al., 1998; Garcia et al., 2000). CPSs are synthesized by transfer of an 
initial monosaccharide phosphate from a nucleotide diphosphate sugar to a 
membrane-associated lipid carrier, followed by the sequential transfer of further 
monosaccharides to produce the lipid-linked repeat unit. This is transferred to the 
outer face of the cytoplasmic membrane by the repeat-unit transporter or flippase, 
polymerized to form the mature CPS, and then attached to the peptidoglycan 
(Sorensen et al., 1990). The cps locus therefore typically encodes the enzymes 
necessary to build the repeat unit, (including an initial glycosyl phosphate 
transferase, and additional transferases responsible for the formation of the 
linkages), to allow the addition of sugars (or other moieties), or otherwise modify the 
repeat unit, as well as the repeat-unit flippase and polymerase (Yother J., 2004). The 
substantial diversity of pneumococcal CPSs is believed to have arisen as a 
consequence of selection for antigenic diversity imposed by the human immune 
system (Spratt et al., 2004). The evolutionary timescales and the genetic events by 
which novel serogroups and serotypes arise are unclear. Comparisons of the 
available cps loci indicate a variety of genetic mechanisms and show that the central 
genes responsible for the synthesis and polymerization of the repeat unit are highly 
variable and often non-homologous between serotypes. These genes have a low 
percentage G+C content, and new serotypes may frequently have been generated by 
the introduction of novel cps genes into pneumococci by lateral gene transfer from 
other species. A much better understanding of the complex mechanisms by which 
antigenic diversity arises could be obtained by analyzing the sequences of the 
complete set of pneumococcal cps loci (Bentley et al., 2006). 
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Fig. 7: Representation of the Wzx/Wzy-Dependent Pathway for Biosynthesis of CPS 9A. Pictured 
is a hypothetical model for capsule biosynthesis in S. pneumoniae based on a mixture of experimental 
evidence and speculation. For a recent review, see Yother 2004. 
1) Non-housekeeping nucleotide sugar biosynthesis. 
2) The initial transferase (WchA in this case) links the initial sugar as a sugar phosphate (Glc-P) to a 
membrane-associated lipid carrier (widely assumed to be undecaprenyl phosphate). 
3) Glycosyl transferases sequentially link further sugars to generate repeat unit. 
4) Wzx flippase transports the repeat unit across the cytoplesmic membrane. 
5) Wzy polymerase links individual repeat units to form lipid-linked CPS. 
6) Wzd/Wze complex translocates mature CPS to the cell surface and may be responsible for the 
attachment to the peptidoglycan. The complex of WchA, Wzy, Wzx, Wzd and Wze shown in the 
membrane is based on that in Figure 2 of Whitfield and Paiment (ref inserire) for the related 
Escherichia coli Type 1 capsule. 
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Pili in Streptococcus pneumoniae. 
The surface-exposed components of a bacterium permit the microorganism to 
assess its environment; hence, these constituents often are major virulence factors. 
Indeed, pili and fimbriae are long filamentous structures that are presented by 
bacteria on their surface. They play a key role in host cell invasion, biofilm formation, 
cell aggregation, DNA transfer and twitching motility as it has been reported in 
different studies (Proft and Baker, 2009). 
The role of pili as adhesive organelles is of particular importance for pathogenic 
bacteria; in fact, they are involved in roles such as attachment to specific host cells 
during colonization, a key step in establishing an infection. 
It has been suggested that bacteria use these structures to form an initial association 
with host cells, which can then be followed by a more “intimate” attachment that 
brings the bacterium into close proximity to the host-cell surface.  
Pili of Gram-negative bacteria are known to adhere to components of the 
extracellular matrix (ECM) and are variable in thickness (from 2 up to 7 nm) and are 
composed by non-covalent homo-polymerized major subunits. 
In contrast, pili in Gram-positive bacteria are long and flexible appendages with a 
diameter ranging from 3 to 10 nm composed by covalently linked major and ancillary 
subunits (assembled by specialized sortase enzymes) which are ultimately covalently 
linked to the peptidoglycan (Telford et al., 2006). Gram-positive pili are usually 
encoded by islets inserted into specific genomic regions, varying in length and 
genetic organization, but sharing characteristic features; all pilus encoding islets 
contain genes coding for: LPxTG or LPxTG-like surface anchored proteins, 
constituting the pilus major and minor components; and sortase enzymes, which are 
specialized transpeptidases involved in pilus assembly.  
Pilus-like strctures on the surface of Gram-positive bacteria were first detected in 
Corynebacterium renale. More recently, surface appendages were reported to be 
present in Actinomyces naeslundii and were subsequently found in other species, 
including Corynebacterium diphtheriae, and many oral Streptococcus spp. (Ton-That 
et al., 2004b). Finally, pili were also characterized in all three of the principal 
streptococcal pathogens that cause invasive disease in humans — group A 
Streptococcus (GAS; that is, Streptococcus pyogenes), group B Streptococcus 
(GBS; that is, Streptococcus agalactiae) and Streptococcus pneumoniae — in which 
they have been shown to have key roles in the adhesion and invasion process and in 
pathogenesis. 
In detail, through the analysis of Streptococcus pneumoniae genomes, two genomic 
elements containing genes typical of Gram-positive pili islets have been identified: 
pilus islet 1 (PI-1) and pilus islet 2 (PI-2) (Barocchi et al., 2006; Bagnoli et al., 2008) 
(Fig. 8). 
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Fig. 8: The genomic organization of pilus-encoding islets in S. pneumoniae. Schematic 
representation of PI-1 and PI-2 (Bagnoli et al., 2008). 
 
 
Both islets were verified to code for pili on the surface of pneumococcal bacteria 
(pilus-1 and pilus-2) and to be not widespread in the S. pneumoniae population. 
Interestingly, molecular epidemiology and genomic analyses demonstrated that 
unlike S. pneumoniae, all S. pyogenes and S. agalactiae isolates encode at least one 
functional pilus, suggesting different roles for pili in these major streptococcal 
pathogens (Falugi et al., 2008; Moschioni et al., 2008). 
In detail, PI-1, first identified in the genome of the TIGR4 strain, is a chromosomal 
region of approximately 12 kb, flanked by two insertion sequences (IS1167) and 
comprising seven genes: rlrA, encoding a RofA-like transcriptional regulator, rrgA, 
rrgB and rrgC, which encode the LPxTG cell-wall anchored pilin subunits, and srtC-1, 
srtC-2 and srtC-3 coding for the three sortases involved in the linkage and assembly 
of the pilus structure on the bacterial surface.  
It has been demonstrated that the major pilin subunit, forming the backbone of the 
pilus, is RrgB, while RrgA and RrgC are the two ancillary pilins, probably localized at 
the opposite extremes of the pilus; RrgA is the pilus adhesin, while the role of RrgC is 
still under investigation (Barocchi et al., 2006; Hilleringmann et al., 2008) (Fig. 9).  
The deletion of all three pilus-associated sortase genes, srtC-1, srtC-2 and srtC-3, 
completely prevent pilus biogenesis, and expression of SrtC-1 alone is sufficient to 
covalently associate RrgB subunits to one another as well as linking the RrgA 
adhesion and RrgC to the polymer (Falker et al., 2008; LeMieux et al., 2008).  
In particular, Falker’s studies suggested that, SrtC-1 and SrtC-2 act as redundant 
pilus subunit polymerases, with SrtC-1 processing all three pilus subunits proteins, 
while SrtC-2 only RrgA and RrgB. In contrast, SrtC-3 seems to have no pilus 
polymerase activity, but appears to be required for wild type focal presentation of the 
pili on the bacterial surface.  
 
 
 
28 
 
 
 
 
                          
 
Fig. 9: Detection of pneumococcal surface exposed pilus structures. A) Immunogold localization 
of RrgB in pilus-1 of S. pneumoniae TIGR4 using α-RrgB antibodies. B) Schematic representation of 
pilus-1 subunits arrangement. 
 
 
PI-2 is similar in its global organization and in its sequence homology to FCT-3 pilus 
islet of S. pyogenes (Teldford et al., 2006). PI-2 islet contains five genes coding for 
two putative sortases (srtG1 and srtG2), a signal peptidase related protein (sipA) 
essential for pilus assembly (but whose role has not yet been established), and two 
LPxTG-type surface anchored proteins (pitB and pitA), where PitB is the backbone 
subunit, and PitA is the ancillary protein. Interestingly, probably due to the different 
functions of the two pili (studies on the possible role of PI-2 in pathogenesis are 
currently ongoing); several copies of pilus-1 are present on the surface of the 
bacteria, whereas only a single copy of pilus-2 is detectable for each diplococcus 
(Fig. 10). 
Independent studies analyzing global S. pneumoniae collections demonstrated that 
in both invasive, acute otitis media and nasopharyngeal clinical isolates the presence 
of PI-1 was correlated with the genotype of the isolate, as defined by multi locus 
sequence typing (MLST), but not with the serotype(Fig.11) (Moschioni et al., 2008; 
Ogunniyi et al., 2007). 
Interestingly, pneumococcal pilus 1 has been reported to be a virulence determinant 
in in vivo animal model studies and its components, RrgA, RrgB and RrgC ( in 
particular RrgB) to be highly immunogenic and to elicit different degrees of protection 
from lethal challenge both in active and passive immunization studies in different 
mouse model of infection (intra-nasal, intra-peritoneal and intravenous challenge). 
For this reason, despite their sequence variability and the limited coverage of these 
antigens, these proteins are currently evaluated as potential candidates to be 
included in a new-generation protein based pneumococcal vaccine (Gianfaldoni et 
al., 2007). 
B 
A 
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Fig. 10 : Electron-microscopy pictures of pilus-2 structure on the S. pneumoniae surface.  
A) Immunogold Electron Microscopy localization of PitB on pili of S. pneumoniae PN110 whole cells. 
B) Double immunogold labeling of pilus-1 and pilus-2, respectively, performed with α-RrgB and α-PitB 
antibodies on 19F Taiwan 14 strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 11. Distribution of PI-1 in a global S. pneumoniae collection. Histograms showing the 
relative frequency of PI-1 positive (black) and PI-1 negative (white) strains within a global 
pneumococcal collection, stratified by Clonal complex (upper histogram) or Serotype. Total number of 
isolates N=424 (Moschioni et al. 2008). 
 
  
 
B 
Pilus-1 
Pilus-2 
A 
30 
 
References 
Adam D. (2009). Issues in pneumococcal disease and pneumococcal conjugate 
vaccines: highlights of the 27th meeting of ESPID. Brussels, Belgium June, 9-13, 
2009. Vaccine 27(50), 7133-7137  
 
Arrecubieta C., Lopez R., Garcia E. (1994). Molecular characterization of cap3A, a 
gene from the operon required for the synthesis of the capsule of Streptococcus 
pneumoniae type 3: Sequencing of mutations responsible for the unencapsulated 
phenotype and localization of the capsular cluster on the pneumococcal 
chromosome. J. Bacteriol. 176, 6375–6383. 
 
Bagnoli F., Moschioni M., Donati C., Dimitrovska V., Ferlenghi I., Facciotti C. Et al. 
(2008). A second pilus type in Streptococcus pneumoniae is prevalent in emerging 
serotypes and mediates adhesion to host cells. J. Bacteriol. 190, 5480-5492 
 
Barocchi M.A., Ries J., Zogaj X., Hemsley C., Albiger B., Kanth A. et al. (2006). A 
pneumococcal pilus influences virulence and host inflammatory responses. Proc. 
Natl. Acad. Sci. USA 103, 2857-2862 
 
Bentley S.D., Aanensen D.M., Mavroidi A., Saunders D., Rabbinowitsch E., Collins 
M. et al. (2006). Genetic analysis of the capsular biosynthetic locus from all 90 
pneumococcal serotypes. PloS Genet. 2, e31 
 
Bogaert D., van Belkum A., Sluijter M., Luijendijk A., de Groot R., Rümke H.C., 
Verbrugh H.A., Hermans P.W. (2004). Colonization by Streptococcus pneumoniae 
and Staphilococcus auresu in healthy children. Lancet 363 (9424), 1871-1872 
 
Cartee R.T., Forsee W.T., Jensen J.W., Yother J. (2001). Expression of the 
Streptococcus pneumoniae type 3 synthase in Escherichia coli. Assembly of type 3 
polysaccharide on a lipid primer. J. Biol. Chem. 276, 48831–48839. 
 
Chan M.S., Maiden M.C., and Spratt B.G. (2001). Database-driven multi locus 
sequence typing (MLST) of bacterial pathogens.  Bioinformatics 17 (11), 1077-1083 
Crimmins E.M., and Finch C.E. (2006). Infection, inflammation, height and longevity. 
Proc. Natl. Acad. Sci. U.S.A. 103, 498-503 
 
Dillard J.P., Vandersea M.W., Yother J. (1995). Characterization of the cassette 
containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus 
pneumoniae. J. Exp. Med.181, 973–983 
Falker S., Nelson A.L., Morfeldt E., Jonas K., Hultenby K., Ries J. et al. (2008). 
Sortase-mediated assembly and surface topology of adhesive pneumococcal pili. 
Mol. Microbiol. 70, 595-607 
 
Falugi F., Zingaretti C., Pinto V., Mariani M., Grandi G. et al. (2008). Sequence 
variation in group A Streptococcus pili and association of pilus backbone types with 
lancefield T serotypes. J. Infect. Dis. 198, 1834-1841 
 
31 
 
Garcia E., Llull D., Munoz R., Mollerach M., Lopez R. (2000). Current trends in 
capsular polysaccharide biosynthesis of Streptococcus pneumoniae. Res. 
Microbiol. 151, 429–435 
 
Gianfaldoni C., Censini S., Hilleringmann M., Moschioni M., Facciotti C., Pansegrau 
W. et al. (2007). Streptococcus pneumoniae pilus subunits protect mice against lethal 
challenge. Infect. Immun. 75, 1059-1062 
 
Givon-Lavi N., Fraser D., Porat N., and Dagan R. (2002). Spread of Streptococcus 
pneumoniae and antibiotic-resistant S. pneumoniae from day-care center attendees 
to their younger siblings: J. Infect. Dis. 186 (11), 1608-1614 
 
Hausedorff W.P., Bryant J., Kloek C., Paradiso P.R., and Siber G. R. (2000). The 
contribution of specific pneumococcal serogroups to different disease manifestations: 
implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30, 
122-140 
 
Higginson J. (1977). The role of the pathologist in environmental medicine and public 
health. Am. J. Pathol. 86, 460-484 
 
Hilleringmann M., giusti F., baudner B.C., Masignani V., Covacci A., Rappuoli R. et 
al. (2008). Pneumococcal pili are composed of profilaments exposing adhesive 
clusters of RrgA. PLoS Pathog. 4, e1000026 
 
Jones K.E., Patel N.G., Levy M.A., Storeygard A., Balk D., Gittleman J.L., and 
Daszak P. (2008). Global trends in emerging infectious diseases. Nature 451, 990-
993 
 
Kolkman M.A., van der Zeijst B.A., Nuijten P.J. (1998). Diversity of capsular 
polysaccharide synthesis gene clusters in Streptococcus pneumoniae. J. Biochem. 
(Tokyo) 123, 937–945 
Last JM: A dictionary of Epidemiology, ed. 2 New York, Oxford University Press, 
1988 
 
LeMieux J., Woody S., and Camilli A. (2008). Roles of the sortases of Streptococcus 
pneumoniae in assembly of the RlrA pilus. J. Bacteriol. 190, 6002-6013 
 
Levin B.R., Lipsitch M., and Bonhoeffer S. (1999). Population biology, evolution and 
infectious diseases: convergence and synthesis. Science 283, 806-809 
 
Llull D., Munoz R., Lopez R., Garcia E. (1999). A single gene (tts) located outside the 
cap locus directs the formation of Streptococcus pneumoniae type 37 capsular 
polysaccharide. Type 37 pneumococci are natural, genetically binary strains. J. Exp. 
Med. 190, 241–251 
 
Mausner J.S., and Bahn A.K. (1974). Epidemiology: an Introductory Text, p. 3-4. The 
W.B. Saunders Co, Philadelphia, Pa. 
 
32 
 
Mavroidi A., Aanensen D.M.,  Godoy D., Skovsted I.C., Kaltoft M.S., Reeves P.R. et 
al. (2007a). Genetic relatedness of the Streptococcus pneumoniae capsular 
biosynthetic loci. J. Bacteriol. 189, 7841-7855 
 
Moschioni M., Donati C., Muzzi A., Masignani V., Censini S., Hanage W.P. et al. 
(2008). Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally 
related. J. Infect. Dis. 197, 888-896 
 
Navarre W.W., and Schneewind O. (1999). Surface proteins of gram-negative 
bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. 
Biol. Rev. 63 (1), 174-229 
 
Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., and Paton J.C. (2007). 
Development of a vaccine against invasive pneumococcal disease based on  
combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75, 
350-357 
 
Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C. and Nahm M.H. 
(2007). Discovery of a new capsular serotype (6C) within serogroup 6 of 
Streptococcus pneumoniae. J. Clin. Microbiol. 45, 1225-1233 
 
Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., 
Jennings G.T., Baldi L., Bartolini E., Capecchi B. et al. (2000). Identification of 
vaccine candidates against serogroup B meningococcus by whole-genome 
sequencing. Science 287, 1816-1820 
 
Proft T., and Baker E.N. (2009). Pili in Gram-negative and Gram-positive bacteria – 
structure, assembly and their role in disease. Cell. Mol. Life Sci. 66, 613-635 
 
Rappuoli R. (2004). From Pasteur to genomics: progress and challenges in infectious 
diseases. Nat. Med. 10, 1177-1185 
 
Rappuoli R. (2007). Bridging the knowledge gaps in vaccine design. Nat. Med. 10, 
1187-1185 
Rappuoli R., Miller H.I., and Falkow S. (2002). Medicine. The intangible value of 
vaccination. Science 297, 937-939 
 
Robbins J.B., Schneerson R., Trollfors B., Sato H., Sato Y., Rappuoli R., and Keith 
J.M. (2005). The diphtheria and pertussis components of diphtheria-tetanus toxoids-
pertussis vaccine should be genetically inactivated mutant toxins. J.Infect. Dis. 191, 
81-88 
 
Rose M., and Zielen S. (2009). Impact of infant immunization programs with 
pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 8(10), 1351-1364  
 
Ryan M.W., and Antonelli P.J. (2000). Pneumococcal antibiotic resistance and rates 
of meningitis in children. Laryngoscope 110 (6), 961-964 
 
Scarselli M., Giuliani M.M., Adu-Bobie J., Pizza M., and Rappuoli R. (2005). The 
impact of genomics on vaccine design. Trends in Biotech. 23(2), 84-91 
33 
 
 
SØrensen U.B., Henrichsen J., Chen H.C., Szu S.C. (1990). Covalent linkage 
between the capsular polysaccharide and the cell wall peptidoglycan of 
Streptococcus pneumoniae revealed by immunochemical methods. Microb. 
Pathog. 8, 325–334. 
 
SØrensen U.B.S., Agger R., Bennedsen J., and Henrichsen J. (1984). 
Phosphorylcholine determinants in six pneumococcal capsular polysaccharides 
detected by monoclonal antibody. Infect. Immyn. 43, 876-878 
 
Spratt B.G., Hanage W.P., Li B., Aanensen D.M., and Feil E.J. (2004). Displaying the 
relatedness among isolates of bacterial species – the eBURST approach. FEMS 
Microbiol. Lett. 241, 129-134 
 
Telford J.L., Barocchi M.A., Margarit I., Rappuoli R., and Grandi G. (2006). Pili in 
gram-positive pathogens. Nat. Rev. Microbiol. 4, 509-519 
Thon-That H., Marraffini L. A., and Schneewind O. (2004). Sortases and pilin 
elements involved in pilus assembly of Corynebacterium diphtheriae. Mol. Microbiol. 
53, 251-261 
 
Ton-That H., Marraffini L.A., and Schneewind O. (2004a). Protein sorting to the cell 
wall envelope of Gram-positive bacteria. Biochim. Biophys. Acta 1694, 269-278 
 
Ton-That H., Marraffini L.A., and Schneewind O. (2004b). Sortases and pilin 
elements involved in pilus assembly of Corynebacterium diphtheriae. Mol. Microbiol. 
53, 251-261 
 
Van Dam J.E.G., Fleer A., and Snippe H. (1990). Immunogenicity and 
immunochemistry of Streptococcus pneumoniae capsular polisaccharides. Antonie 
Leeuwenhock 58, 1-47 
 
Waite R.D., Penfold D.W., Struthers J.K., Dowson C.G. (2003). Spontaneous 
sequence duplications within capsule genes cap8E and tts control phase variation in 
Streptococcus pneumoniae serotypes 8 and 37. Microbiology 149, 497–504 
 
Williams B.G., Gouws E., Boschi-Pinto C., Bryce J., and Dye C. (2002). Estimates of 
world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. 
Dis. 2, 25-32 
 
World Health Organization (2007). Pneumococcal conjugate vaccine for childhood 
immunization – WHO position paper. Wkly. Epidemiol. Record 82, 93-104 
 
Yother J. Capsule. In: Tuomanen EI, editor. The pneumococcus. Washington (D. C.): 
ASM Press; 2004 
 
 
 
34 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
 
 
Assessment of Streptococcus pneumoniae PI-1 
prevalence in carried and transmitted isolates from 
mother-infant pairs on the Thailand-Burma border*. 
 
 
        *Based on 
 
 
Paul Turner1,2,3, Sara Melchiorre4, Monica Moschioni4, Michèle A. Barocchi4, 
Claudia Turner1,2,3, Wanitda Watthanaworawit1,2, Napaphat Kaewcharernnet1,2, 
François Nosten1,2,3, and David Goldblatt5 
 
1
Shoklo Malaria Research Unit, Mae Sot 63110, Thailand 
2
Mahidol-Oxford Tropical Medicine Research Unit, Bangkok 10400, Thailand 
3
Centre for Tropical Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom 
4
Novartis Vaccines and Diagnostics s.r.l., Siena 53100, Italy 
5
 Immunobiology Unit, Institute of Child Health, University of London, London WC1N 1EH,    United 
Kingdom 
 
 
 
 
 
 
 
 
36 
 
Introduction 
 
Streptococcus pneumoniae is a significant global pathogen (O'Brien et al., 2009). 
Additionally, pneumococcus is a nasopharyngeal commensal and infants are 
frequently colonised (Hill et al., 2008; Bogaert et al., 2004). Various cell-surface 
components, including pneumococcal surface adhesin A (PsaA), choline-binding 
protein A (CbpA), pneumococcal serine-rich repeat protein (PsrP) and pneumococcal 
adherence-virulence factor A (PavA) have been demonstrated to contribute to 
nasopharyngeal adherence and colonisation, but their mechanisms of action remain 
incompletely understood (Rajam et al., 2008; Rosenow et al., 1997; Shivshankar et 
al., 2009; Pracht et al., 2005). The RrgA subunit of the surface exposed pilus-1 
filamentous structure also enhances pneumococcal adherence to respiratory 
epithelial cells in vitro (Nelson et al., 2007; Barocchi et al., 2006). Pneumococcal 
pilus-1 is encoded by the pilus islet-1 (PI-1; rlrA islet) and is composed of three 
subunits, RrgA, RrgB, and RrgC (Barocchi et al., 2006; Hava et al., 2002; LeMieux et 
al., 2006). Since immunization with pilus antigens is protective against lethal 
intraperitoneal challenge in a mouse model, pilus subunits are regarded as potential 
candidates for inclusion in a protein-based pneumococcal vaccine (Gianfaldoni et al., 
2007). However, PI-1 presence is not universal: studies of predominantly invasive 
pneumococci have found that PI-1 is present in isolates from a limited number of 
serotypes (particularly those included in the 7-valent conjugate vaccine, PCV7) and 
that its presence correlates with genotype by Multi Locus Sequence Typing (MLST) 
(Basset et al., 2007; Moschioni et al., 2008; Aguiar et al., 2008; Moschioni et al., 
2010; Imai et al., 2010; Donati et al., 2010). Given the prevalence of asymptomatic 
colonisation, and that serotype/genotype structure of invasive pneumococci is not 
stable (Black et al., 2010), further work to describe the prevalence and function of the 
pilus-1 in pneumococcal carriage strains is warranted. 
With this respect, our aims were to: i) determine PI-1 prevalence in pneumococcal 
carriage isolates from infants and their mothers; ii) determine which PI-1 positive 
clones were associated with carriage in the study region; iii) explore the possible 
functions of the pilus in vivo, and in particular evaluate whether PI-1 presence had an 
effect on pneumococcal transmission or carriage duration. 
 
 
 
Material and Methods 
 
 
Pneumococcal isolates 
 
Isolates characterized in this work were collected from 2007-2010, during a 
longitudinal carriage and pneumonia study of 965 infants at Maela refugee camp, 
Thailand. Maela was established in 1984, and ~40,000 Burmese refugees, 
predominantly of Karen ethnicity, live in a 4km2 area. Pneumococcal vaccines are not 
available in the camp. Nested within the study was a sub-cohort of 234 infant-mother 
pairs who were studied in more detail: between 1 - 24 months of age, these infants 
had a nasopharyngeal swab (NPS) and blood taken at monthly surveillance visits 
and their mothers had an NPS taken at the same time. NPSs were processed using 
the WHO pneumococcal colonization protocol as previously described (O'Brien et al., 
2003; Turner et al., 2011). All morphologically distinct pneumococcal isolates from 
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each swab culture were serotyped by latex agglutination (Adegbola et al., 2006). 
Non-typeable (NT) pneumococci, either morphologically typical pneumococcal 
colonies (likely encapsulated organisms) or rough colonies (likely non-encapsulated 
organisms) that were non-reactive with typing antisera, were confirmed by bile 
solubility and absent capsular swelling with Omniserum (Statens Serum Institute, 
Denmark). Serotype 6C was identified by PCR (Park et al., 2007). 
Mother and infant pneumococcal carriage patterns for the first twelve months of 
follow-up were reviewed and isolates chosen for further analysis using the definitions 
described below. 
 
Definition of carriage and transmission 
 
We defined a carriage episode within a mother-infant pair as the identification of 
the same pneumococcal serotype in ≥2 NPS (from mother and/or infant), separated 
by ≤2 NPS negative for that serotype. This definition was relaxed for serotypes 1 and 
5, known to be carried for very short durations, where a single positive NPS could 
define a carriage episode. 
Transmission of a pneumococcus was defined as the presence of an identical 
pneumococcal serotype and MLST genotype in both mother and infant at the same 
visit (“concordant transmission”) or when isolated from the mother and the infant 
during a carriage episode but not at the same visit (“discordant transmission”). A non-
transmitted pneumococcus was a carried serotype that never appeared in the other 
member of the mother-infant pair during the carriage episode as defined above 
(Table 1 and Supplementary Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Definition of carriage and transmission. 
 
 
 
 
 
Carriage episode. The same serotype identified in at least two NPS, 
separated by ≤2 negative NPS (exception: serotypes 1 and 5). 
Non-transmitted. A carried pneumococcus that never appears in the 
other member of the mother-infant pair.  
Transmitted – concordant. Identical pneumococci (serotype + 
MLST) identified from a mother and baby at the same visit. 
Transmitted – discordant. Identical pneumococci identified from a 
mother and baby during a carriage episode (but not on the same visit). 
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Supplementary Fig.1: Example of pneumococcal transmission event. (A) non-transmission of 
serotypes 19F and NT; (B) concordant transmission of serotype 6B; (C) discordant transmission of 
serotype 23F. Horizontal arrows represent an infant’s first year of life, with the numbers indicating age 
in months. Pneumococcal serotypes shown above these arrows represent carried isolates from the 
infant and those below the arrows are from the mother. Shading highlights the criteria used to select 
isolates for PI-1 PCR and MLST. 
 
 
 
PI-1 detection 
 
PI-1 presence was determined as previously described (Moschioni et al., 2008). 
Briefly, PCRs were performed directly from bacteria using the primers listed in the 
Table 2. Primers were designed on conserved regions on the boundaries of PI-1 
(459for, 470rev) and within PI-1 (P01rev, P11for, P08for, P08rev).  
   
     
 
Table 2: PI-1 PCR primer sets 
Forward primer Sequence (5’→3’) Reverse primer Sequence (5’→3’) 
459 for  AACTGAATTGACACAACGTGTCTT 470 rev GCCACACAAGATGTTGATGCTTTT 
459 for AACTGAATTGACACAACGTGTCTT P01 rev AGCGACAAGCCACTGTATCATATT 
P08 for TGAGATTTTCTCGTTTCTCTTAGC P08 rev AATAGACGATGGGTATTGATCATGT 
P11for GCCATTTGGATCAGCTAAAAGTT   
 
39 
 
Multi Locus Sequence Typing 
 
MLST was performed as previously described (Enright et al., 1998). Briefly, 
PCR amplifications were performed directly from the bacteria using the standard 
primer pairs. Sequences were obtained on both strands using an ABI 3730xl DNA 
Analyzer (Life Technologies Corporation, USA). Sequence type (ST) was determined 
using the MLST website (http://spneumoniae.mlst.net). eBURST 
(http://spneumoniae.mlst.net/eburst/) was run with default settings on the entire 
MLST database and each ST assigned to a clonal complex (CC) (Feil et al., 2004). 
CCs were named in accordance with the ST number of the founder predicted by 
eBURST. 
 
 
 Statistical analysis 
 
Statistical analyses were carried out using STATA 10.1 (StataCorp, USA). 
Chi-squared test, Fisher’s exact test, and odds ratios were used to compare 
proportions. Carriage duration was estimated by survival analysis methods, using the 
Log-rank test to compare groups. First pneumococcal acquisition was defined as 
midpoint between the last negative swab and the first positive swab for a given 
serotype. Termination of the carriage episode was similarly defined as the midpoint 
between the first of two consecutive negative swabs and the last positive swab for 
the serotype (Hill et al., 2008). 
 
 
Study ethics 
 
Ethical approval for the carriage study was granted by Mahidol University, 
Thailand and Oxford University, UK. 
 
 
Results 
 
 
Pneumococcal isolates and PI-1 prevalence 
 
In the first twelve months of follow-up, 4.927 surveillance NPS were collected 
from the 234 mother-infant pairs (85% of expected). 2,496 pneumococci were 
cultured and 896 (35.9%) of these isolates were included in the current work. Thirty-
four serotypes were contained in the strain selection: these serotypes accounted for 
90.1% (2.250/2.496) of isolates in the entire cohort strain collection. 
We successfully determined the PI-1 status of 887/896 (98.9%) isolates: 35.2% 
(312/887) were positive. PI-1 positive isolates were restricted to 10 serotypes: 4, 6A, 
6B, 9, 14, 19F, 19A, 23F, 33C, and NT (Fig. 1).  
 
PI-1 and transmission 
 
To analyse whether PI-1 presence had an effect on pneumococcal transmission 
within the mother-infant pairs, a panel of strains was selected and analysed by both 
PI-1 PCR and MLST (to define genotype). We elected to study serotypes contained 
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in, or related to, current conjugate vaccines (PCV13 + 6C) as well as non-typeable 
pneumococci which were overrepresented in our population (the commonest 
pneumococcal “type” identified from mother swabs and the third commonest in 
infants). In the first year of follow-up, these serotypes accounted for 69.6% and 
59.8% of pneumococci carried by infants and mothers, respectively. In the case of a 
potentially transmitted pneumococcal serotype, i.e. isolates carried by both mother 
and infant at the same visit, or at  
sequential visits, single isolates from both mother and infant were selected for study. 
For non-transmitted pneumococci, i.e. pneumococci carried by only the mother or 
infant, a single isolate from the carriage episode was studied. Additionally, we 
analyzed every isolate from carriage episodes of all serotypes in eight mother-infant 
pairs to determine the clonality of pneumococcal carriage. 
Of the 489 isolates selected for the primary analysis, PI-1 PCR was 
uninterpretable in six, resulting in 483 analyzable pneumococcal isolates. Overall, 
219/483 (45.3%) of these isolates were PI-1 positive. PI-1 was found in non-typeable 
pneumococci and in 6/14 serotypes studied, all of which, apart from one 19A isolate, 
were PCV7 serotypes (Table 3).  
PI-1 was found most frequently in 19F (91%) and 23F (77%) although these 
serotypes, according to the MLST and eBURST analyses, were dominated by a 
single clonal complex each (CC271 – 19F; CC802 – 23F). Overall, PI-1 positive 
pneumococci were members of a restricted group of clonal complexes (Figure 2). 
By serotyping a representative isolate alone, 253/483 (52.4%) pneumococci would 
have been classified as transmitted (153 concordant; 100 discordant) and 230/483 
(47.6%) as non-transmitted. Combining MLST and serotype, nine concordant and 
eight discordant “transmitted” isolates (17/483; 3.5%) were reclassified as non-
transmitted, resulting in a final total of 236/483 (48.9%) transmitted and 247/483 
(51.1%) non-transmitted pneumococci. 
PI-1 presence was not correlated with transmission: 47.5% (112/236) of 
transmitted and 43.3% (107/247) of non-transmitted pneumococci were PI-1 positive, 
with an odds ratio of 1.2 (95% CI: 0.8 – 1.7; p=0.4), and no significant differences at 
the individual serotype level. 
We analysed an additional 91 pneumococcal isolates, from seven mother-infant 
pairs and one mother-twin infant unit, to confirm that sequential isolates of the same 
serotype in an individual, and isolates of the same serotype in a mother-infant pair, 
were indeed identical. In all mother-infant pairs each serotype carried was 
represented by a single ST per carriage/transmission episode with three exceptions 
(Supplementary Table 2). 
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Fig. 1: PI-1 presence by serotype in 887 carried pneumococci (includes all commonly carried 
serotypes). 
 
 
 
 
    
 
 
Fig. 2. PI-1 presence by clonal complex in 483 carried pneumococci (PCV13 serotypes plus 6C 
and NT only). 
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Table 3. Pneumococcal serotype distribution and isolate transmission category in mother-
infant pairs (PCV13 serotypes plus 6C and NT). 
 
 
 
 
 
Serotype Total, 
N 
Transmitted*, 
N (% within serotype) 
PI-1 present, 
N (% within serotype) 
1 12 4 (33.3) 0 (0.00) 
3 11 4 (36.4) 0 (0.00) 
4 4 2 (50.0) 0 (0.00) 
5 10 2 (20.0) 0 (0.00) 
6A 16 6 (37.5) 0 (0.00) 
6B 54 27 (50.0) 29 (53.7) 
6C 15 4 (26.7) 0 (0.00) 
7F 5 2 (40.0) 0 (0.00) 
9V 8 4 (50.0) 5 (62.5) 
14 46 28 (60.9) 15 (32.6) 
18C 7 4 (57.1) 0 (0.00) 
19F 89 50 (56.2) 81 (91.0) 
19A 14 4 (28.6) 1 (7.1) 
23F 82 38 (46.3) 63 (76.8) 
NT 110 57 (51.8) 25 (22.7) 
Total 483 236 (48.9) 219 (45.3) 
 1 
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PI-1 and first pneumococcal carriage episode duration in infants 
 
To analyse the correlation between PI-1 presence and the duration of infant 
carriage, we determined the PI-1 status of 316 isolates from first carriage episodes of 
all common serotypes (i.e. all first episodes of carriage of each serotype, not 
necessarily an infant’s first ever pneumococcal carriage episode). We inferred the PI-
1 status for the entire carriage episode from the PI-1 PCR result of a single isolate. 
We included all carriage episodes, even where a pneumococcal serotype was 
identified only in a single NPS. 
Given the well described association of shorter carriage in individuals with prior 
pneumococcal exposure, we subsequently focused our analysis on only first ever 
episodes of carriage (i.e. one per infant) (Hill et al., 2008). From the 316 carriage 
episodes selected, we identified 216 analysable first ever carriage episodes: PI-1 
PCR data was available for at least one isolate in 180 of these (90 PCV13 serotypes, 
58 non-vaccine serotypes, and 32 non-typeable pneumococci). Median and mean 
durations of the first pneumococcal carriage episode were 63 days (95% CI: 61 – 91) 
and 105 days (95% CI: 91 – 119) respectively, but varied considerably by serotype 
(Table 4).  
Comparing the 180 carriage episodes where PI-1 PCR results were available, PI-1 
positive carriage episodes (51/180; 28.3%) were significantly longer than those 
associated with a PI-1 negative organism (median 152 days (95% CI: 93 – 213) vs. 
61 days (95% CI: 57 – 90); mean 177 days (95% CI: 137 – 218) vs 84 days (95% CI: 
72 – 97); p<0.0001). However, the analysis of carriage duration was confounded by 
serotype. In our study serotypes 19F and 23F had the longest duration of carriage 
and were both predominantly PI-1 positive. To analyze the relative contribution of 
serotype and PI-1 to carriage duration we fitted a Cox regression model and found 
that, stratifying carriage by serotype, PI-1 presence was not associated with a 
significant change in carriage duration (hazard ratio 0.7 (95% CI: 0.4 – 1.2; p=0.2)). 
 
 
 
 
   
Table 4. First pneumococcal carriage episode duration (six commonest serotypes). 
 
 
Serotype 
Number of 
episodes 
Median carriage duration, 
days (95% CI) 
Mean carriage duration, 
days (95% CI) 
6B 13 121 (90 – 153) 119 (93 – 145) 
14 8 62 (30 – 151) 86 (45 – 128) 
19F 21 213 (63 – 243) 231 (154 – 308) 
23F 21 184 (62 – 277) 176 (124 – 229) 
35F 9 121 (30 – 180) 124 (66 – 182) 
NT 33 31 (31 – 61) 72 (44 – 99) 
 1 
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Discussion 
 
This study is the largest investigation of the prevalence and possible function of 
the PI-1 encoded pilus in carriage isolates of S. pneumoniae. It also provides 
pneumococcal strain data from SE Asia, a densely populated region under-
represented in the pneumococcal carriage and disease epidemiology literature. As 
serotypes are commonly used as the basis for defining transmission, we were 
interested in the frequency with which a molecular analysis may confound the 
analysis of transmission. By genotyping, discrepancies were discovered in only 3.5% 
of transmission events classified by serotype. We also demonstrated that 
pneumococci of the same serotype are predominantly clonal within a discrete 
carriage episode. We therefore concluded that serotype can be used to define 
transmission events and carriage episodes with relatively high confidence, but the 
inclusion of genotyping is vital to ensure complete accuracy. 
Because of the selection criteria for isolates included in the study, we cannot 
describe the overall pilus prevalence for the population. However, in the 887 carriage 
isolates analysed the pilus prevalence was 35.2%. Of the 34 serotypes analysed we 
found that PI-1was only present in non-typeable isolates and nine other serotypes: 
65% of PCV7 isolates were PI-1 positive compared with 9% of non-vaccine 
serotypes. Interestingly, Basset et al., examining nasopharyngeal and invasive 
pneumococcal isolates from the American Indian collection, also found that PCV7 
strains were significantly more likely to be PI-1 positive than non-vaccine serotypes, 
but the overall proportion of PI-1 positive isolates was slightly lower (Basset et al., 
2007). They, along with other authors, demonstrated that PI-1 positive strains were 
contained within a small number of clonal complexes (Moschioni et al., 2008; Aguiar 
et al., 2008; Moschioni et al., 2010). Indeed, in the current study we demonstrated 
that PI-1 positive isolates were clustered predominantly within four dominant clonal 
complexes (CC15, CC271, CC315, CC802). The strong association between 
serotype/clonal complex and pilus presence, along with strain selection criteria, and 
the different regional distribution of the clones may explain the variability in PI-1 
prevalence between different studies. 
We did not demonstrate a pilus-attributable effect on pneumococcal 
transmissibility. However, there are limitations to our study which may be important 
confounders for this analysis. The carriage study was carried out in a densely 
populated refugee camp where 13% of the population are <5 years old and there is 
likely to be frequent transmission of nasopharyngeal organisms both within families 
and between members of the community. Despite using a combination of serotype 
and sequence type to increase the accuracy of our transmissibility categories, we 
cannot exclude the possibility that “non-transmitted” strains were effectively 
transmitted between mother or infant and others but not detected by us. Several 
studies have documented the clustering of pneumococcal serotypes and genotypes 
within families, which highlights the difficulty of assigning a definitive “non-
transmitted” label to isolates collected from an incomplete household group 
(Melegraro et al., 2004; Reis et al., 2008). However, we focused on mother-infant 
transmission since we felt that the absence of a strain in one member of this pair 
would be the best marker for relative non-transmissibility in the early months of life. In 
addition, we included both concordant and discordant time-point pneumococcal 
serotype/ST identifications in the mother-infant pair as “transmitted”, as long as they 
occurred no more than two months apart. However, the study sampling frequency 
may have been too low to demonstrate transmission of serotypes carried for very 
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short durations. Also, in the presence of multiple serotype carriage, a common 
occurrence in infancy and one that is underestimated by standard culture protocols 
(Turner et al., 2011), a particular serotype may become undetectable for a period of 
time before re-emerging as the dominant serotype which may result in incorrect 
categorisation regarding transmissibility. 
Although in the crude analysis PI-1 presence was associated with longer first 
pneumococcal carriage episode in infants, we could find no significant association 
between carriage duration and PI-1 at the individual serotype level. This is likely to be 
the result of the low numbers of carriage episodes of individual serotypes (resulting in 
wide confidence intervals around the carriage duration estimates) and the restricted 
number of clones within each serotype. We could have increased the number of 
carriage episodes included in our analysis by looking at all carriage episodes of each 
serotype rather than restricting to each infants first ever carriage episodes, but this 
would have introduced other confounding factors, such as the impact of previous 
carriage and immune factors in subsequent carriage episode duration. 
In conclusion, we found that SE Asian pneumococcal carriage isolates had 
similar pilus prevalence to previously described strain collections, which is helpful in 
the on-going assessment of likely global coverage of a pilus subunit-containing 
vaccine. Despite its known role in pneumococcal attachment, we could not determine 
a clear impact of PI-1 presence on transmissibility or carriage duration. 
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Supplementary Table 2. Detailed study of pneumococcal carriage in the first year of life in eight 
mother-infant pairs. Pneumococcal serotypes and their MLST genotype (in parentheses) are given 
for each nasopharyngeal sampling point. 
 
 
 
 
 
 
Infant 
age (m) 
1 2 3 4 5 6 7 8 9 10 11 12 
Pair 1 
Infant     
19A 
(230) 
19A 
(230) 
14 
(63) 
14  
(63) 
14  
(63) 
NT 
(4133) 
6C 
(4420) 
6C 
(4420) 
NT 
(4133) 
6C 
(4420) 
6C 
(4420) 
Mother     
35F 
(4418) 
14 
(63) 
            
7F 
(3545) 
7F 
(3545) 
Pair 2 
Infant   
NT 
(4136) 
NT 
(4136) 
NT 
(4136) 
  
NT 
(4136) 
NT 
(4136) 
NT 
(4136) 
NT 
(4136) 
NT 
(4136) 
    
Mother 
NT 
(4136) 
  
7F 
(3545) 
7F 
(3545) 
NT 
(4136) 
7F 
(3545) 
7F 
(3545) 
7F 
(3545) 
NT 
(4136) 
7F 
(3545) 
NT 
(4136) 
NT 
(4136) 
NT 
(4136) 
Pair 3 
Infant   
14 
(63) 
14 
(63) 
14 
(63) 
NT 
(4451) 
14 
(63) 
14 
(63) 
  
19F 
(81) 
22A 
(910) 
19F 
(81) 
22A 
(910) 
Mother 
32A 
(5092) 
32A 
(5092) 
32A 
(5092) 
NT 
(5121) 
14 
(63) 
NT 
(4451) 
14 
(4451) 
NT 
(4451) 
32A 
(5092) 
  
NT 
(4451) 
19F 
(81) 
Pair 4 
  Infant     
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
23F 
(802) 
19F 
(4414) 
19F 
(4414) 
23F 
(802) 
Mother 
37 
(447) 
37 
(447) 
    
37 
(447) 
37 
(447) 
  
37 
(447) 
37 
(447) 
    
19F 
(4414) 
Infant 
age (m) 
1 2 3 4 5 6 7 8 9 10 11 12 
Pair 5 (twins) 
Infant 
1 
NT 
(448) 
33C 
(5096) 
33C 
(5096) 
17F 
(5098) 
21 
(5103) 
21 
(5103) 
19F 
(5106) 
19F 
(5106) 
19F 
(4414) 
19F 
(4414) 
6A 
(4936) 
19F 
(4414) 
NT 
(448) 
Infant 
2 
  
17F 
(5098) 
21 
(5103) 
21 
(5103) 
17F 
(5098) 
21 
(5103) 
21 
(5103) 
21 
(5103) 
  
19F 
(4414) 
6A 
(4936) 
6A 
(4936) 
Mother 
NT 
(448) 
  
1 
(217) 
    
NT 
(448) 
            
Pair 6 
Infant   
NT 
(4133) 
NT 
(4133) 
19B 
(5095) 
1 
(217) 
NT 
(4133) 
9V 
(280) 
9V 
(280) 
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
19F 
(4414) 
Mother 
19B 
(5095) 
19B 
(5095) 
    
NT 
(4133) 
    
9V 
(5123) 
9V 
(280) 
      
Pair 7 
Infant 
45 
(5097) 
45 
(5097) 
23F 
(802) 
23F 
(802) 
23F 
(802) 
  
6B 
(315) 
  
23F 
(802) 
23F 
(802) 
23F 
(802) 
  
Mother   
23F 
(802) 
  
23F 
(802) 
23F 
(802) 
6B 
(315) 
        
23F 
(802) 
  
Pair 8 
Infant     
23F 
(4413) 
    
23F 
(4413) 
23F 
(4413) 
23F 
(4413) 
23F 
(4413) 
  
23F 
(4413) 
  
Mother         
23F 
(4413) 
          
23F 
(4413) 
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Introduction 
 
The Gram-positive pathogen Streptococcus pneumoniae is a major cause of 
community acquired pneumonia as well as of upper respiratory tract infections such 
as acute otitis media and sinusitis, and invasive diseases like meningitis, bacteremia, 
and endocarditis. However, S. pneumoniae is also a commensal of the upper 
respiratory tract, especially of young children, which represent the reservoir for 
pneumococcal transmission within the community. 
The ability of the pneumococcus to invade sterile sites is related to the expression of 
a polysaccharide capsule, which provides a barrier against host-cell mediated 
phagocytosis and allows bacterial persistence in the blood (Brown et al., 1983). In 
addition, capsular polysaccharides (CPSs) are immunogenic and antibodies against 
CPSs provide protection against pneumococcal diseases; therefore, all of the current 
pneumococcal vaccines are based on a combination of different CPSs, either 
unconjugated or conjugated to a carrier protein (Gladstone et al., 2011). 
To date, 93 capsular types (serotypes) have been described on the basis of their 
different genetic, biochemical and antigenic properties (Bentley et al., 2006; Calix et 
al., 2010; Park et al., 2007). Each pneumococcal serotype corresponds to a distinct 
CPS, synthesized on the bacterial surface by enzymes which are encoded within a 
single chromosomal locus (cps) with few remarkable exceptions (Llull et al., 1999). 
The sequencing of different cps loci revealed the presence of a core of genes 
common to all capsular types, namely wzg, wzh, wzd, and wze (also known as cpsA, 
B, C and D), and of additional genes that are CPS-specific (Bentley et al., 2006).  
The different capsular types can be distinguished in the laboratory by reaction 
with type specific antisera, evidenced by the capsular swelling or Quellung reaction 
(Austrian R., 1976). Only a minority of S. pneumoniae strains does not react with the 
anticapsular antisera; these strains, defined as non-typeable pneumococci (NTPn), 
are thought to be non-encapsulated. NTPn are typically isolated from carriage 
(Andrade et al., 2010; Sa-Leao et al., 2006), but are also found in conjunctivitis 
(Carvalho et al., 2003), acute otitis media (Xu et al., 2011) and, rarely, in invasive 
diseases (Beall et al., 2006). Non-typeability can be due to different genetic 
modifications such as partial or complete loss of the cps gene cluster (Hathaway et 
al., 2004), presence of a novel gene (Baldry et al., 2009), single point mutations 
(Arrecubieta et al., 1994) or sequence duplications (Waite et al., 2001 ). 
The characterization of NTPn by multi locus sequence typing (MLST), revealed the 
presence of specific NT pneumococcal lineages which had lost the cps (Hanage et 
al., 2006;  Hathaway et al., 2004) as well as of NTPn that were genetically related to 
encapsulated strains (Andrade et al., 2010; Hathaway et al., 2004). 
In this report, we investigated the genetic basis for non-typeability of two NTPn 
isolates responsible for invasive disease. The strains were isolated in the same 
Italian hospital during 2006 through the surveillance network of invasive 
pneumococcal disease (Gherardi et al., 2009) from two cases of bacteremic 
pneumonia. 
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Material and Methods 
 
 
Bacterial strains and growth conditions 
 
S. pneumoniae AP422 and AP426 were isolated from the blood of two adult 
patients with pneumonia admitted to the same Italian hospital in 2006. S. 
pneumoniae AP425 (clinical isolate, serotype 7F) was used as a control. Strains 
were grown at 37°C in 5% CO2-enriched atmosphere on Columbia agar plates 
(Oxoid, Cambridge, UK) with 5% sheep blood or on Tryptic Soy Agar plates (Becton 
Dickinson, Cockeysville, MA) supplemented with 10 mg/l colistine, 5 mg/l oxolinic 
acid and 5% sheep blood. For genomic DNA extraction and NMR spectroscopy, 
liquid cultures were grown statically at 37°C in 5% CO2 in Todd Hewitt Broth (Becton 
Dickinson, Cockeysville, MA) supplemented with 0.5% (w/w) yeast extract (THYE) 
until an A600 = 0.25. 
 
Serotyping 
 
Serotyping was performed by means of the Latex agglutination test and the Quellung 
reaction using antisera produced by the Statens Serum Institute (Copenhagen, 
Denmark). 
 
Multi Locus sequence typing (MLST) 
 
Genomic DNA from pneumococcal strains was prepared with the Wizard Genomic 
DNA purification kit (Promega, Madison, WI, USA) following the manufacturer’s 
instructions. MLST was performed as previously described (Moschioni et al., 2008). 
 
7F cps detection and sequencing 
 
The amplification and sequencing of 7F cps was performed on the genomic 
DNA of strains AP422, AP426 and AP425 with the primers listed in Table S1. 
Amplicons were purified with magnetic carboxilate beads (Agentcourt, Bioscience, 
Beverly, MA, USA); sequencing was carried 6 out by use of an ABI 3730xl DNA 
Analyzer (Applied Biosystems, Carlsbad, CA, USA). Traces were visually inspected, 
edited, assembled and analyzed with Vector NTI Advance 10.3.1 (Life technologies, 
Carlsbad, CA, USA). 
 
Cloning and S. pneumoniae transformation 
 
The shuttle plasmid pMU1328_Pc_wchA was obtained as described below. 
Briefly, the wchA gene of the AP425 strain and the constitutive promoter of 
erythromycin (Pc) (Gentile et al., 2011) were amplified with the primers wchA_for 
GTGCGTGGATCCATGGATGAAAAAGGATTGAAAATT, wchA_rev 
CAGCGTGGATCCTCACTTCGCCCCTTCTCTCATAAA, and Pc_for 
GTGCGTGAATTCGAAACAGCAAAGAATGGCGGAAAC, Pc_rev  
CAGCGTGGATCCGTAATCACTCCTTCTTAATTACAA, respectively. The two PCR 
products, digested with BamHI and EcoRI-BamHI restriction enzymes, respectively, 
were cloned into pMU1328, containing an erythromycin resistance marker (Achen et 
al., 1986). The ligations mixtures were then transformed into competent Escherichia 
54 
 
coli DH10B and transformants were selected on plates supplemented with 
erythromycin (100 μg/ml). Pc_wchA insertion was confirmed by sequencing. 
pMU1328_Pc_wchA was then transformed in AP422 and AP426 by using 
conventional methods (Alloing et al., 1998) and transformants were selected using 
erythromycin (1μg/ml), analyzed by PCR to confirm the presence of the plasmid, and 
further investigated for the presence of the capsule. 
 
Transmission Electron Microscopy 
 
For ultrastructural analysis of the polysaccharide capsule, bacterial strains 
were grown on Columbia agar plates and were prepared following the immune-
stabilization method (Jacques et al., 1997). Briefly, bacteria were resuspended in 0.5 
ml of PBS pH 7.4 and incubated with 0.1 ml of type 7 antiserum (Statens Serum 
Institute) for 1 hr at 4°C. After immune-stabilization, bacterial cells were centrifuged 
at 2500 g for 10 minutes at 4°C and fixed in fixation solution containing 2.5 % (v/v) 7 
glutaraldehyde, 0.075 M lysine acetate in cacodylate buffer (0.1 M, pH 7.0) with 
0.075% (w/v) ruthenium red (CR buffer) for 2 hrs at 4°C. Controls processed using an 
unrelated antiserum (type 21), or without antiserum stabilization, were performed 
simultaneously. All bacterial samples were then washed three times with CR buffer 
and post-fixed with 1% (w/v) osmium tetroxide in CR buffer for 1 h at RT. 
Subsequently, samples were washed three times with cacodylate buffer, dehydrated 
through a graded series of ethanol and embedded in Agar 100 epoxy resin. Ultrathin 
sections of bacterial samples were placed on formvar-coated copper grids, post-
stained with uranyl acetate and lead citrate, and examined with a Philips 208s 
electron microscope at 80 kV. 
 
Type 7F capsular polysaccharide detection by high-resolution magic angle 
spinning NMR spectroscopy (HR-MAS NMR) 
 
Bacteria recovered from THYE were inactivated by 1% v/v formaldehyde 
treatment and then washed three times with PBS in deuterium oxide (D2O, Sigma-
Aldrich, St. Louis, MO, USA). 
Approximately 50 μl of compact pellet were inserted in a Kel-F disposable insert for 
50 μl volume and then in a 4 mm MAS ZrO2 rotor (Bruker, Madison, WI, USA). 
Proton HR-MAS NMR experiments were recorded by a Bruker Avance III 400 MHz 
spectrometer using a Bruker 4-mm HR-MAS probe. The spectra were recorded at 
4500 Hz spin rate and 25°C. The 1H spectra were acquired with the combination of a 
diffusion filter pulse sequence with gradient pulses (diffusion filter 85%), to remove 
the low molecular weight species free in solution, and a Carr-Purcell-Meiboom-Gill 
(CPMG) pulse sequence [90-(τ-180-τ)n-acquisition] as T2 filter (76.8 ms), to remove 
the broad signals of larger molecular species. 5 mg of purified 7F polysaccharide 
(Merck & Co., Whitehouse Station, NJ, USA) were solubilized in 0.75 ml of D2O 
(D2O, Sigma-Aldrich, St. Louis, MO, USA), the solution inserted in 5-mm NMR tube 
(Wilmad, Vineland, NJ, USA) and proton NMR experiment recorded at 25°C by the 
same spectrometer, using a 5-mm broadband probe (Bruker, Madison, WI, USA). 1H 
NMR spectrum was recorded using a standard one-pulse 8 experiment. Both the 
solid- and liquid-state NMR spectra were collected with 32 k data points over a 10 
ppm spectral width. The transmitter was set at the HDO frequency, which was also 
used as reference signal (4.79 ppm). The TOPSPIN 2.1 software package (Bruker, 
Madison, WI, USA) was used for data acquisition and processing of all spectra. 
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Results 
 
 
S. pneumoniae NT invasive strains AP422 and AP426 contain a 7F capsular 
locus with point mutations in wchA. 
 
The two invasive S. pneumoniae strains AP422 and AP426 were defined NT since 
serotype testing (confirmed by the Statens Serum Institute, Copenhagen) did not 
reveal positivity for any capsular type. In order to verify if these strains belonged to a 
clonal lineage specifically referable to NT pneumococci, they were subjected to 
MLST analysis. Both AP422 and AP426 were ST191, which, according to a search 
performed on the S. pneumoniae MLST database (www.mlst.net, accessed on 
08.18.2011), is mainly (96%) associated with serotype 7F. Using PCR amplification, 
7F cps was detected in both AP422 and AP426 and then sequenced. Comparison 
with two reference 7F cps sequences (GenBank accession numbers CR931643 and 
ABFT01000009) revealed the presence of the entire 7F locus with an overall 
nucleotide identity of 99.8% in both strains. Sequence analysis highlighted the 
existence of a distinct single point mutation in the wchA gene in both strains. With 
respect to the reference wchA nucleotide sequence, AP422 wchA showed a deletion 
of an adenine in position 910 and AP426 wchA a G1081T transvertion. Both 
mutations led to the formation of a premature stop codon associated with the 
translation of a protein truncated at the C-terminus (Fig. 1). Since the NCBI 
Conserved Domain algorithm (www.ncbi.nlm.nih.gov/structure/cdd/cdd.shtml) 
predicts the WchA catalytic domain to be at the C-terminus of the protein (Fig. 1), the 
truncated WchA proteins coded by AP422 and AP426 are predicted to be 
enzymatically inactive. In the polysaccharide biosynthesis pathway, WchA (also 
known as CpsE) is the initial glucose phosphate-transferase, responsible for the 
linkage of an activated glucose phosphate to the lipid carrier (Pelosi et al., 2005). 
Since WchA has been demonstrated to be required for the biosynthesis of other 
capsular types ( Pelosi et al., 2005), the mutations identified in wchA in both AP422 
and AP426 are likely to be responsible for their non-typeability. 
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Fig. 1: Alignment of the WchA amino acids sequences of the reference strain 554/62 (GenBank 
accession number CR931643) and the two NTPn AP422 and AP426. In both AP422 and AP426 
wchA is translated as a C-terminal truncated protein. Bold types indicate the catalytic domain as 
predicted by NCBI Conserved Domain; italic types indicate an alternative C-terminus due to a frame 
shift in the nucleotide sequence of AP422. 
 
Over-expression of a functional WchA restores the ability of S. pneumoniae to 
synthesize the 7F capsule. 
 
With the aim to demonstrate that the mutations present in wchA were sufficient to 
account for the lack of capsule in AP422 and AP426, a functional WchA was over-
expressed in both NTPn strains. AP422 and AP426 were transformed with the 
recombinant plasmid pMU1328_Pc_wchA to generate the respective recombinant 
strains AP422pMU1328_Pc_wchA and AP426pMU1328_Pc_wchA. The two 
transformed NTPn yielded a positive reaction with the 7F antiserum in the Quellung 
reaction. To confirm that WchA over-expression had restored the ability to synthesize 
a capsule at levels comparable to a wild type capsulated strain, the NTPn isolates 
along with their WchA over-expressing derivatives were analyzed by TEM and by 
HR-MAS NMR using the serotype 7F strain AP425 as a positive control. For TEM 
analysis, the two NTPn strains along with AP425 and the WchA over-expressing 
derivatives were stabilized with type 7 antiserum before processing for TEM 
observation. This method was chosen as an alternative of the standard fixation 
protocol with lysine and ruthenium red (Hammerschmidt et al., 2005); indeed, the 
latter appeared inadequate to visualize the 7F capsule polysaccharide (data not 
shown) since it does not contain anionic charged moieties (Moreau et al., 1988). 
After immune-stabilization a well-preserved dense and thick capsular material was 
surrounding the AP425 bacterial cells (Fig. 2a), while non-typeable AP422 (Fig. 2b) 
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and AP426 (Fig. 2c) did not exhibit any characteristic polysaccharide layer on the 
surface. In WchA over-expressing AP422 and AP426 (Fig. 2d and 2e) TEM 
examination revealed cells surrounded by a capsular polysaccharide structure 
comparable to that of AP425, although the capsule of WchA over-expressing AP422 
appeared slightly irregular. In order to confirm the data obtained by TEM, proton HR-
MAS NMR spectra directly recorded on inactivated cells in the heterogeneous phase 
was performed. 1H NMR spectrum collected on purified polysaccharide in liquid state 
clearly revealed specific peaks corresponding to the 7F capsular polysaccharide, 
such as the anomeric protons at 5.05.6 ppm and the C6 methyl group of rhamnose 
at 1.21.4 ppm (Fig. 3a). Spectra analysis showed the absence of the 7F specific 
peaks in the two NTPn and in AP422 and AP426 transformed with an empty 
pMU1328 plasmid (Fig. 3b) while the above mentioned 7F specific peaks were 
present both in the capsulated AP425 and in the WchA over-expressing AP422 and 
AP426 (Fig. 3b). Although signals of other 1H-NMR sensitive molecules expressed on 
the bacterial surface are partially overlapped with the capsular polysaccharide peaks, 
the anomeric proton at 5.6 ppm and the C6 methyl group of Rhamnose at 1.2-1.4 
ppm fall in spectral windows without other peaks and the assignment results certain. 
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Fig. 2: Transmission Electron Microscopy (TEM) of S. pneumoniae strains incubated with type 
7 antiserum and stained with ruthenium red. (a): AP425 (serotype 7F); (b): AP422 (NT); (c): AP426 
(NT); (d): WchA over-expressing AP422 strain; (e): WchA over-expressing AP426 strain. Over-
expression of WchA restored capsule production in both AP422 and AP426. 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
Fig. 3: Proton NMR spectra of 7F purified polysaccharide and S. pneumoniae strains. (a) 
Schematic representation of the chemical structure of 7F polysaccharide. (b) Proton HR-MAS NMR 
spectra recorded in heterogeneous phase on inactivated bacterial cells. The presence or the absence 
of the capsule on the bacterial surface, based on spectra analysis, is indicated for each strain. Red 
arrows indicate anomeric proton at 5.6 ppm, while blue arrows indicate the C6 methyl group of 
rhamnose at 1.21.4 ppm. 7F purified polysaccharide solubilised in denaturated water is used as a 
positive control. 
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Discussion 
 
It is commonly assumed that NTPn lack the polysaccharide capsule, the principal 
pneumococcal virulence factor that acts by protecting the bacteria during the early 
phase of infection. Capsule deficiency impairs the capability of NTPn to evade the 
host's immune defence so that only rarely these strains are able to persist in the 
blood and cause invasive disease. Indeed, very few cases of invasive diseases due 
to NTPn have been reported in large epidemiological studies (Beall et al., 2006).  
In this study, we have investigated the molecular basis responsible for non-
typeability of two NT strains isolated from cases of bacteremic pneumonia in the 
same hospital during the same year. Molecular analysis of the two invasive NTPn, 
revealed that these strains were genetically related, since both belonged to ST191 
and carried the 7F cps. However, they presented distinct point mutations in the wchA 
gene that were responsible for their non-encapsulated phenotype. wchA is 
responsible for the first step of capsule biosynthesis, since it codes for a 
glycosyltransferase that catalyzes the transfer of the initial sugar to a lipid acceptor, 
thus initiating the synthesis of the capsule repeat units (Pelosi et al., 2005). Both 
mutations, introducing a premature stop codon in wchA, are expected to produce a 
glycosyltransferase truncated in its catalytic domain (Pelosi et al., 2005). Re-
establishment of a functional wchA in both NTPn restored the 7F capsule production 
as clearly demonstrated by serotyping, TEM and HR-MAS NMR. HR-MAS 
spectroscopy appeared as a powerful methodology for detection and identification of 
the bacterial capsule and to confirm its identity. In fact, although precise 
quantification of the polysaccharide capsule content could not be provided due to the 
variable number of cells used as input in the analysis, this method clearly gave a 
semi-quantitative estimation of the specific polysaccharide expressed on the bacterial 
surface. 
Our report is the first describing naturally occurring wchA mutations responsible 
for the NT phenotype in pneumococci. The essentiality of wchA for capsular 
assembly has previously been shown in laboratory mutants of other S. pneumoniae 
serotypes. Insertion-duplication mutagenesis or introduction of a premature stop 
codon in wchA made pneumococci of serotype 19F, 14, 9N, 13 and 15B unable to 
produce the capsule (Guidolin et al., 1994; Kolkman et al., 1996; Kolkman et al., 
1998). Furthermore, sequence duplications within wchA was found to be responsible 
for capsular phase variation in sorbarods-generated pneumococci of serotypes 3, 8 
and 37 (Waite et al., 2001; Waite et al., 2003). Hathaway et al. reported that in 
approximately 30% of naturally occurring NTPn the cps was present. Non-typeability 
was assumed to be due to mutations in the cps genes, but sequencing was not 
performed and the gene(s) involved remained unknown (Hathaway et al., 2004).  
In conclusion, this study identified two new point mutations, involving wchA, 
responsible for the unencapsulated phenotype in two NTPn isolated from invasive 
disease. In addition, it provides evidence regarding the key role of wchA in serotype 
7F capsule biosynthesis process. It remains to be ascertained whether wchA is prone 
to point mutations, leading to the loss of capsule, also in other NTPn strains.  
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girare pagina, iniziare un nuovo capitolo. 
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scontri, incomprensioni ma solo perché volevamo il meglio l’una per l’altra, come 
“due sorelline”. 
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“La mia Gabri”…per lei non ci sono parole, per il rapporto, il nostro rapporto, non ci 
sono parole. Il legame che ci unisce è qualcosa davvero di raro, unico, 
assolutamente non scontato e facile da poter trovare. 
Ci siamo incontrate dopo la prima settimana di università e non ci siamo più lasciate. 
Nove anni di vita vissuti insieme, vicine, gomito a gomito, senza mai un litigio, direi 
quasi assurdo, da non credere! Eppure è così, ci siamo sempre confrontate, aiutate 
ma mai accusate, siamo state sempre il sostegno l’una dell’altra, sincere più che mai, 
leali, sempre presenti. 
Ora ci siamo separate e non sai, non puoi immaginare, cosa è significato per me. 
Sento un vuoto, un’assenza forte, a volte enorme…mi sento sola. 
Anche se so perfettamente che ci saremo sempre l’una per l’altra, anche a mille 
miglia di distanza; perché lo sai Ga, le cose VERE, profonde non scompariranno mai. 
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Grazie per aver supportato i miei studi e la mia ricerca, che con Monica avete 
studiato a tavolino per permettermi di raggiungere obiettivi elevati che mi 
garantissero un ottimo livello di ricerca. 
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Abstract
Streptococcus pneumoniae pilus islet-1 (PI-1)-encoded pilus enhances in vitro adhesion to the respiratory epithelium and may contribute to
pneumococcal nasopharyngeal colonization and transmission. The pilus subunits are regarded as potential protein vaccine candidates. In
this study, we sought to determine PI-1 prevalence in carried pneumococcal isolates and explore its relationship with transmissibility or
carriage duration. We studied 896 pneumococcal isolates collected during a longitudinal carriage study that included monthly nasopha-
ryngeal swabbing of 234 infants and their mothers between the ages of 1 and 24 months. These were cultured according to the WHO
pneumococcal carriage detection protocol. PI-1 PCR and genotyping by multilocus sequence typing were performed on isolates chosen
according to specific carriage and transmission definitions. Overall, 35.2% of the isolates were PI-1-positive, but PI-1 presence was
restricted to ten of the 34 serotypes studied and was most frequently associated with serotypes 19F and 23F; 47.5% of transmitted and
43.3% of non-transmitted isolates were PI-1-positive (OR 1.2; 95% CI 0.8–1.7; p 0.4). The duration of first-ever infant pneumococcal
carriage was significantly longer with PI-1-positive organisms, but this difference was not significant at the individual serotype level. In
conclusion, PI-1 is commonly found in pneumococcal carriage isolates, but does not appear to be associated with pneumococcal trans-
missibility or carriage duration.
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Introduction
Streptococcus pneumoniae is a significant global pathogen [1].
Additionally, pneumococcus is a nasopharyngeal commensal,
and infants are frequently colonized [2,3]. Various cell sur-
face components, including pneumococcal surface adhesin A,
choline-binding protein A, pneumococcal serine-rich repeat
protein, and pneumococcal adherence-virulence factor A,
have been shown to contribute to nasopharyngeal adherence
and colonization, but their mechanisms of action remain
incompletely understood [3–7]. The RrgA subunit of the sur-
face exposed pilus-1 filamentous structure also enhances
pneumococcal adherence to respiratory epithelial cells in vitro
[8,9]. Pneumococcal pilus-1 is encoded by the pilus islet-1
(PI-1; rlrA islet), and is composed of three subunits: RrgA,
RrgB, and RrgC [9–11]. As immunization with pilus antigens
is protective against lethal intraperitoneal challenge in a
mouse model, pilus subunits are regarded as potential candi-
dates for inclusion in a protein-based pneumococcal vaccine
[12]. However, PI-1 presence is not universal: studies of pre-
dominantly invasive pneumococci have found that PI-1 is
present in isolates from a limited number of serotypes
ª2011 The Authors
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(particularly those included in the pneumococcal seven-valent
conjugate vaccine (PCV7)) and that its presence correlates
with genotype by multilocus sequence typing (MLST) [13–
18]. Given the prevalence of asymptomatic colonization, and
the fact that the serotype/genotype structure of invasive
pneumococci is not stable [19], further work to describe the
prevalence and function of pilus-1 in pneumococcal carriage
strains is warranted.
In this study, our aims were to: (i) determine PI-1 preva-
lence in pneumococcal carriage isolates from infants and
their mothers; (ii) determine which PI-1-positive clones were
associated with carriage in the study region; and (iii) explore
the possible functions of the pilus in vivo, and in particular
evaluate whether PI-1 presence had an effect on pneumococ-
cal transmission or carriage duration.
Materials and Methods
Pneumococcal isolates
The isolates characterized in this work were collected from
2007 to 2010, during a longitudinal carriage and pneumonia
study of 965 infants at Maela refugee camp, Thailand. Maela
was established in 1984, and c. 40 000 Burmese refugees,
predominantly of Karen ethnicity, live in a 4-km2 area. Pneu-
mococcal vaccines are not available in the camp. Nested
within the study was a subcohort of 234 mother–infant pairs
who were studied in more detail: between 1 and 24 months
of age, these infants had a nasopharyngeal swab (NPS) and
blood taken at monthly surveillance visits, and their mothers
had an NPS taken at the same time. NPSs were processed
according to the WHO pneumococcal colonization protocol,
as previously described [20,21]. All morphologically distinct
pneumococcal isolates from each swab culture were sero-
typed by latex agglutination [22]. Non-typeable (NT) isolates,
either morphologically typical pneumococcal colonies (proba-
bly encapsulated organisms) or rough colonies (probably non-
encapsulated organisms) that were non-reactive with typing
antisera, were confirmed by bile solubility and absent capsular
swelling with Omniserum (Statens Serum Institute, Hillerod,
Denmark). Serotype 6C was identified by PCR [23].
Mother and infant pneumococcal carriage patterns for the
first 12 months of follow-up were reviewed, and isolates
were chosen for further analysis according to the definitions
described below.
Definition of transmission and carriage
Transmission of a pneumococcus was defined as the pres-
ence of an identical pneumococcal serotype and MLST geno-
type in both mother and infant at the same visit
(‘concordant transmission’) or when the pneumococcus was
isolated from the mother and the infant during a ‘transmissi-
bility episode’ but not at the same visit (‘discordant transmis-
sion’). A non-transmitted pneumococcus was a carried
serotype that never appeared in the other member of the
mother–infant pair during the transmissibility episode as
defined below (Fig. S1). Transmissibility episodes were identi-
fied by carriage within a mother–infant pair when there was
the same pneumococcal serotype cultured from two or
more NPSs (from mother and/or infant), separated by two
or fewer NPSs negative for that serotype. For serotypes 1
and 5, which are known to be carried for very short dura-
tions, a single positive NPS could define non-transmission.
For the determination of carriage duration in infants, a
pneumococcal acquisition was defined as midpoint between
the last negative swab and the first positive swab for a given
serotype. Termination of the carriage episode was similarly
defined as the midpoint between the first of two consecutive
negative swabs and the last positive swab for the serotype.
PI-1 detection
PI-1 presence was determined as previously described [14].
Briefly, PCRs were performed directly from bacteria, with the
primers listed in Table S1. Primers were designed on con-
served regions on the boundaries of PI-1 (459for and 470rev)
and within PI-1 (P01rev, P11for, P08for, and P08rev).
MLST
MLST was performed as previously described [24]. Briefly,
PCR amplifications were performed directly from the bacte-
ria with the standard primer pairs. Sequences were obtained
on both strands with an ABI 3730xl DNA Analyzer (Life
Technologies Corporation, Carlsbad, CA, USA). Sequence
type (ST) was determined by use of the MLST website
(http://spneumoniae.mlst.net). eBURST (http://spneumoniae.
mlst.net/eburst/) was run with default settings on the entire
MLST database, and each ST was assigned to a clonal com-
plex (CC) [25]. CCs were named in accordance with the ST
number of the founder predicted by eBURST.
Statistical analysis
Statistical analyses were carried out with STATA 10.1 (Stata-
Corp, College Station, TX, USA). The chi-squared test, Fish-
er’s exact test and ORs were used to compare proportions.
Carriage duration was estimated by survival analysis methods,
with the log-rank test being used to compare groups [2].
Study ethics
Ethical approval for the carriage study was granted by Mah-
idol University, Thailand and Oxford University, UK.
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Results
Pneumococcal isolates and PI-1 prevalence
In the first 12 months of follow-up, 4921 surveillance NPS
were collected from the 234 mother–infant pairs (84.7% of
expected). In total, 2497 isolates were cultured, and 896
(35.9%) of these were included in the current work. All iso-
lates meeting the criteria described below were included,
resulting in 34 serotypes being represented in the isolate
selection. These serotypes accounted for 90.1% (2251/2497)
of isolates in the entire cohort isolate collection.
We successfully determined the PI-1 status of 887/896
(98.9%) isolates: 35.2% (312/887) were positive. PI-1-positive
isolates were restricted to ten serotypes: 4, 6A, 6B, 9, 14,
19F, 19A, 23F, 33C, and NT (Fig. 1).
PI-1 and transmission
To determine whether PI-1 presence had an effect on pneu-
mococcal transmission within the mother–infant pairs, a
panel of isolates was selected and analysed by both PI-1 PCR
and MLST (to define genotype). We elected to study sero-
types contained in, or related to, current conjugate vaccines
(PCV13 + 6C), as well as NT isolates, which were overrep-
resented in our population (the commonest pneumococcal
‘type’ identified from mother swabs, and the third common-
est in infants). In the first year of follow-up, these serotypes
accounted for 69.6% and 59.8% of isolates carried by infants
and mothers, respectively. In the case of a potentially trans-
mitted pneumococcal serotype, i.e. isolates carried by both
mother and infant at the same visit, or at sequential visits,
single isolates from both mother and infant were selected
for study. For non-transmitted isolates, i.e. isolates carried
by only the mother or infant, a single isolate was studied.
Additionally, we analysed every isolate from carriage epi-
sodes of all serotypes in eight mother–infant pairs to deter-
mine the clonality of pneumococcal carriage.
Of the 489 isolates selected for the primary analysis, PI-1
PCR was uninterpretable in six, resulting in 483 analysable
isolates. Overall, 219/483 (45.3%) of these were PI-1 posi-
tive. PI-1 was found in NT isolates and in 6/14 serotypes
studied, all of which, apart from one 19A isolate, were PCV7
serotypes (Table 1). PI-1 was found most frequently in 19F
(91%) and 23F (77%) isolates, although these serotypes,
according to the MLST and eBURST analyses, were domi-
nated by a single CC each (19F, CC271; 23F, CC802). Over-
all, PI-1-positive isolates were members of a restricted group
of CCs (Fig. 2).
With serotyping of a representative isolate alone, 253/483
(52.4%) isolates would have been classified as transmitted
(153 concordant; 100 discordant) and 230/483 (47.6%) as
non-transmitted. With a combination of MLST and serotype,
nine concordant and eight discordant ‘transmitted’ isolates
(17/483; 3.5%) were reclassified as non-transmitted, resulting
FIG. 1. Pilus islet-1 (PI-1) presence by serotype in 887 carried pneumococcal isolates (includes all commonly carried serotypes).
TABLE 1. Pneumococcal serotype distribution and isolate
transmission category in mother–infant pairs (pneumococ-
cal 13-valent conjugate vaccine serotypes plus 6C and non-
typeable (NT))
Serotype Total, N Transmitteda, N
(% within serotype)
PI-1 present, N
(% within serotype)
1 12 4 (33.3) 0 (0.00)
3 11 4 (36.4) 0 (0.00)
4 4 2 (50.0) 0 (0.00)
5 10 2 (20.0) 0 (0.00)
6A 16 6 (37.5) 0 (0.00)
6B 54 27 (50.0) 29 (53.7)
6C 15 4 (26.7) 0 (0.00)
7F 5 2 (40.0) 0 (0.00)
9V 8 4 (50.0) 5 (62.5)
14 46 28 (60.9) 15 (32.6)
18C 7 4 (57.1) 0 (0.00)
19F 89 50 (56.2) 81 (91.0)
19A 14 4 (28.6) 1 (7.1)
23F 82 38 (46.3) 63 (76.8)
NT 110 57 (51.8) 25 (22.7)
Total 483 236 (48.9) 219 (45.3)
PI-1, pilus islet-1.
aConcordant and discordant transmission combined.
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in final totals of 236/483 (48.9%) transmitted and 247/483
(51.1%) non-transmitted isolates. PI-1 presence was not cor-
related with transmission: 47.5% (112/236) of transmitted
and 43.3% (107/247) of non-transmitted isolates were PI-1
positive, with an OR of 1.2 (95% CI 0.8–1.7; p 0.4), and no
significant differences were seen at the individual serotype
level.
We analysed an additional 91 isolates, from seven
mother–infant pairs and one mother–twin infant unit, to con-
firm that sequential isolates of the same serotype in an indi-
vidual, and isolates of the same serotype in a mother–infant
pair, were indeed identical. In all mother–infant pairs, each
serotype carried was represented by a single ST per car-
riage/transmission episode, with three exceptions (Table S2).
PI-1 and first pneumococcal carriage episode duration in
infants
To analyse the correlation between PI-1 presence and the
duration of infant carriage, we determined the PI-1 status of
316 isolates from the first carriage episodes of all common
serotypes (defined as serotypes with at least ten carriage
episodes). These episodes included first episodes of carriage
of each serotype, not only an infant’s first ever pneumococ-
cal carriage episode. We inferred the PI-1 status for the
entire carriage episode from the PI-1 PCR result of a single
isolate.
Given the well-described association of shorter carriage in
individuals with prior pneumococcal exposure, we subse-
quently focused our analysis only on first-ever episodes of
carriage (i.e. one per infant) [2]. From the 316 carriage epi-
sodes selected, we identified 216 analysable first-ever car-
riage episodes: PI-1 PCR data were available for at least one
isolate in 180 of these (90 pneumococcal 13-valent conjugate
vaccine serotypes, 58 non-vaccine serotypes, and 32 NT
pneumococci). Median and mean durations of the first
pneumococcal carriage episode were 63 days (95% CI 61–
91) and 105 days (95% CI 91–119), respectively, but varied
considerably by serotype (Table 2). On comparison of the
180 carriage episodes where PI-1 PCR results were available,
PI-1-positive carriage episodes (51/180; 28.3%) were signifi-
cantly longer than those associated with a PI-1-negative
organism (median 152 days (95% CI 93–213) vs. 61 days
(95% CI 57–90); mean 177 days (95% CI 137–218) vs.
84 days (95% CI 72–97); p <0.0001). However, the analysis
of carriage duration was confounded by serotype. In our
study, serotypes 19F and 23F had the longest duration of
carriage, and were both predominantly PI-1-positive. To
analyse the relative contributions of serotype and PI-1 to
carriage duration, we fitted a Cox regression model and
found that, on stratification of carriage by serotype, PI-1
presence was not associated with a significant change in
carriage duration (hazard ratio 0.7 (95% CI 0.4–1.2; p 0.2)).
Discussion
This study is the largest investigation of the prevalence and
possible function of the PI-1-encoded pilus in carriage iso-
lates of S. pneumoniae. It also provides pneumococcal strain
data from Southeast Asia, a densely populated region that is
under-represented in the pneumococcal carriage and disease
epidemiology literature. As serotypes are commonly used as
the basis for defining transmission, we were interested in the
FIG. 2. Pilus islet-1 (PI-1) presence by clonal complex in 483 carried pneumococcal isolates (pneumococcal 13-valent conjugate vaccine sero-
types plus 6C and non-typeable (NT) only).
TABLE 2. First pneumococcal carriage episode duration (six
commonest serotypes)
Serotype
Number
of episodes
Median carriage
duration (days)
(95% CI)
Mean carriage
duration (days)
(95% CI)
6B 13 121 (90–153) 119 (93–145)
14 8 62 (30–151) 86 (45–128)
19F 21 213 (63–243) 231 (154–308)
23F 21 184 (62–277) 176 (124–229)
35F 9 121 (30–180) 124 (66–182)
NT 33 31 (31–61) 72 (44–99)
NT, non-typeable.
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frequency with which a molecular analysis may confound the
analysis of transmission. By genotyping, discrepancies were
discovered in only 3.5% of transmission events classified by
serotype. We also demonstrated that pneumococci of the
same serotype are predominantly clonal within a discrete
carriage episode. We therefore concluded that serotype can
be used to define transmission events and carriage episodes
with relatively high confidence, but that the inclusion of
genotyping is vital to ensure complete accuracy.
Because of the selection criteria for the isolates included
in the study, we cannot describe the overall pilus prevalence
for the population. However, in the 887 carriage isolates
analysed, the pilus prevalence was 35.2%. Among the 34 ser-
otypes analysed, we found that PI-1 was present only in NT
isolates and nine other serotypes: 65% of PCV7 isolates
were PI-1-positive, as compared with 9% of non-vaccine ser-
otypes. Interestingly, Basset et al., examining nasopharyngeal
and invasive pneumococcal isolates from the American Indian
collection, also found that PCV7 strains were significantly
more likely to be PI-1-positive than non-vaccine serotypes,
but that the overall proportion of PI-1-positive isolates was
slightly lower [13]. They, along with other authors, demon-
strated that PI-1-positive strains were contained within a
small number of CCs [14–16]. Indeed, in the current study,
we demonstrated that PI-1-positive isolates were clustered
predominantly within four dominant CCs (CC15, CC271,
CC315, and CC802). The strong association between sero-
type/CC and pilus presence, along with strain selection crite-
ria, and the different regional distribution of the clones, may
explain the variability in PI-1 prevalence between different
studies.
We did not demonstrate a pilus-attributable effect on
pneumococcal transmissibility. However, there are limitations
to our study that may be important confounders for this
analysis. The carriage study was carried out in a densely pop-
ulated refugee camp where 13% of the population are
<5 years old, and there is likely to be frequent transmission
of nasopharyngeal organisms both within families and
between members of the community. Despite the use of a
combination of serotype and ST to increase the accuracy of
our transmissibility categories, we cannot exclude the possi-
bility that ‘non-transmitted’ strains were effectively transmit-
ted between mother or infant and others but not detected
by us. Several studies have documented the clustering of
pneumococcal serotypes and genotypes within families, which
highlights the difficulty of assigning a definitive ‘non-transmit-
ted’ label to isolates collected from an incomplete household
group [26,27]. However, we focused on mother–infant trans-
mission, because we felt that the absence of a strain in one
member of this pair would be the best marker for relative
non-transmissibility in the early months of life. In addition,
we included both concordant and discordant time-point
pneumococcal serotype/ST identifications in the mother–
infant pair as ‘transmitted’, as long as they occurred no more
than 2 months apart. However, the study sampling frequency
may have been too low to demonstrate transmission of ser-
otypes carried for very short durations. Also, in the pres-
ence of multiple serotype carriage, a common occurrence in
infancy and one that is underestimated by standard culture
protocols [21], a particular serotype may become undetect-
able for a period of time before re-emerging as the dominant
serotype, and this may result in incorrect categorization
regarding transmissibility.
Although, in the crude analysis, PI-1 presence was associ-
ated with longer first pneumococcal carriage episodes in
infants, we could find no significant association between car-
riage duration and PI-1 at the individual serotype level. This
is likely to be the result of the low numbers of carriage epi-
sodes of individual serotypes (resulting in wide CIs around
the carriage duration estimates) and the restricted number
of clones within each serotype. We could have increased the
number of carriage episodes included in our analysis by look-
ing at all carriage episodes of each serotype rather than
restricting our investigation to each infant’s first-ever car-
riage episodes, but this would have introduced other con-
founding factors, such as the impact of previous carriage and
immune factors on subsequent carriage episode duration.
Therefore, it is possible that, as a result the study sample
size, a small effect of pilus on either transmission or carriage
duration may have been missed.
In conclusion, we found that Southeast Asian pneumococ-
cal carriage isolates had a similar pilus prevalence to to that
in previously described strain collections, which is helpful in
the ongoing assessment of likely global coverage of a pilus
subunit-containing vaccine. Despite its known role in pneu-
mococcal attachment, we could not determine a clear impact
of PI-1 presence on transmissibility or carriage duration.
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SUMMARY 30 
 31 
Non-typeable Streptococcus pneumoniae (NTPn) strains are typically isolated from nasopharyngeal 32 
carriage or from conjunctivitis. Since the isolation of NTPn from invasive disease is rare, we 33 
characterized the genetic basis for non-typeability of two isolates obtained in Italy from two cases 34 
of bacteremic pneumonia. Multi Locus Sequence Typing (MLST) revealed that both NTPn 35 
belonged to ST191, which, according to the MLST database, is associated with serotype 7F. 36 
Sequencing of the capsular locus (cps) confirmed the presence of a 7F cps in both strains and 37 
revealed the existence of distinct single point mutations in the wchA gene (a glycosyltransferase), 38 
both leading to the translation of proteins truncated at the C-terminus. To verify if these mutations 39 
were responsible for non-typeability of the isolates, a functional 7F WchA was over-expressed in 40 
both NTPn. The two NTPn along with their WchA over-expressing derivatives were analyzed by 41 
Transmission Electron Microscopy and by high-resolution magic angle spinning NMR 42 
spectroscopy. Both NTPn were devoid of a polysaccharide capsule and WchA over-expression was 43 
sufficient to restore the assembly of a serotype 7F capsule on the surface of the two NTPn. In 44 
conclusion, we identified two new naturally-occurring point-mutations leading to the non-45 
typeability in pneumococcus and demonstrated that WchA is essential for the biosynthesis of the 46 
serotype 7F capsule. 47 
 48 
 3 
 
INTRODUCTION 49 
 50 
The Gram-positive pathogen Streptococcus pneumoniae is a major cause of community acquired 51 
pneumonia as well as of upper respiratory tract infections such as acute otitis media and sinusitis, 52 
and invasive diseases like meningitis, bacteremia, and endocarditis. However, S. pneumoniae is also 53 
a commensal of the upper respiratory tract, especially of young children, which represent the 54 
reservoir for pneumococcal transmission within the community.  55 
The ability of the pneumococcus to invade sterile sites is related to the expression of a 56 
polysaccharide capsule, which provides a barrier against host-cell mediated phagocytosis and 57 
allows bacterial persistence in the blood (Brown et al., 1983). In addition, capsular polysaccharides 58 
(CPSs) are immunogenic and antibodies against CPSs provide protection against pneumococcal 59 
diseases; therefore, all of the current pneumococcal vaccines are based on a combination of 60 
different CPSs, either unconjugated or conjugated to a carrier protein (Gladstone et al., 2011).  61 
To date, 93 capsular types (serotypes) have been described on the basis of their different genetic, 62 
biochemical and antigenic properties (Bentley et al., 2006; Calix & Nahm, 2010; Park et al., 2007). 63 
Each pneumococcal serotype corresponds to a distinct CPS, synthesized on the bacterial surface by 64 
enzymes which are encoded within a single chromosomal locus (cps) with few remarkable 65 
exceptions (Llull et al., 1999). The sequencing of different cps loci revealed the presence of a core 66 
of genes common to all capsular types, namely wzg, wzh, wzd, and wze (also known as cpsA, B, C 67 
and D), and of additional genes that are CPS-specific (Bentley et al., 2006).  68 
The different capsular types can be distinguished in the laboratory by reaction with type-specific 69 
antisera, evidenced by the capsular swelling or Quellung reaction (Austrian, 1976). Only a minority 70 
of S. pneumoniae strains does not react with the anticapsular antisera; these strains, defined as non-71 
typeable pneumococci (NTPn), are thought to be non-encapsulated. NTPn are tipically isolated 72 
from carriage (Andrade et al., 2010; Sa-Leao et al., 2006), but are also found in conjunctivitis 73 
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(Carvalho et al., 2003), acute otitis media (Xu et al., 2011)  and, rarely, in invasive diseases (Beall 74 
et al., 2006). Non-typeability can be due to different genetic modifications such as partial or 75 
complete loss of the cps gene cluster (Hathaway et al., 2004), presence of a novel gene (Baldry et 76 
al., 2009), single point mutations (Arrecubieta et al., 1994) or sequence duplications (Waite et al., 77 
2001). 78 
The characterization of NTPn by multilocus sequence typing (MLST), revealed the presence of 79 
specific NT pneumococcal lineages which had lost the cps (Hanage et al., 2006; Hathaway et al., 80 
2004) as well as of NTPn that were genetically related to encapsulated strains (Andrade et al., 2010; 81 
Hathaway et al., 2004).  82 
In this report, we investigated the genetic basis for non-typeability of two NTPn isolates responsible 83 
for invasive disease. The strains were isolated in the same Italian hospital during 2006 through the 84 
surveillance network of invasive pneumococcal disease (Gherardi et al., 2009) from two cases of 85 
bacteremic pneumonia.  86 
87 
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METHODS 87 
 88 
Bacterial strains and growth conditions. S. pneumoniae AP422 and AP426 were isolated from 89 
the blood of two adult patients with pneumonia admitted to the same Italian hospital in 2006. S. 90 
pneumoniae AP425 (clinical isolate, serotype 7F) was used as a control. Strains were grown at 91 
37°C in 5% CO2-enriched atmosphere on Columbia agar plates (Oxoid, Cambridge, UK) with 5% 92 
sheep blood or on Tryptic Soy Agar plates (Becton Dickinson, Cockeysville, MA) supplemented 93 
with 10 mg/l colistine, 5 mg/l oxolinic acid and 5% sheep blood. For genomic DNA extraction and 94 
NMR spectroscopy, liquid cultures were grown statically at 37°C in 5% CO2 in Todd Hewitt Broth 95 
(Becton Dickinson, Cockeysville, MA) supplemented with 0.5% (w/w) yeast extract (THYE) until 96 
an A600 = 0.25.  97 
 98 
Serotyping. Serotyping was performed by means of the Latex agglutination test and the Quellung 99 
reaction using antisera produced by the Statens Serum Institute (Copenhagen, Denmark).  100 
 101 
Multi Locus Sequence Typing (MLST). Genomic DNA from pneumococcal strains was prepared 102 
with the Wizard Genomic DNA purification kit (Promega, Madison, WI, USA) following the 103 
manufacturer’s instructions. MLST was performed as previously described (Bagnoli et al., 2008). 104 
 105 
7F cps detection and sequencing. The amplification and sequencing of 7F cps was performed on 106 
the genomic DNA of strains AP422, AP426 and AP425 using the primers listed in Table S1, 107 
generating short overlapping DNA fragments. Amplicons were purified with magnetic carboxilate 108 
beads (Agentcourt, Bioscience, Beverly, MA, USA); sequencing was carried out by use of an ABI 109 
3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA). Traces were visually inspected, 110 
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edited, assembled and analyzed with Vector NTI Advance 10.3.1 (Life technologies, Carlsbad, CA, 111 
USA).  112 
 113 
Cloning and S. pneumoniae transformation. The shuttle plasmid pMU1328_Pc_wchA was 114 
obtained as described below. Briefly, the wchA gene of the AP425 strain and the constitutive 115 
promoter of erythromycin (Pc) (Gentile et al., 2011) were amplified with the primers wchA_for 116 
GTGCGTGGATCCATGGATGAAAAAGGATTGAAAATT, wchA_rev 117 
CAGCGTGGATCCTCACTTCGCCCCTTCTCTCATAAA, and Pc_for 118 
GTGCGTGAATTCGAAACAGCAAAGAATGGCGGAAAC, Pc_rev 119 
CAGCGTGGATCCGTAATCACTCCTTCTTAATTACAA, respectively. The two PCR products, 120 
digested with BamHI and EcoRI-BamHI restriction enzymes, respectively, were cloned into 121 
pMU1328, containing an erythromycin resistance marker (Achen et al., 1986). The ligations 122 
mixtures were then transformed into competent Escherichia coli DH10B and transformants were 123 
selected on plates supplemented with erythromycin (100 µg/ml). Pc_wchA insertion was confirmed 124 
by sequencing. pMU1328_Pc_wchA was then transformed in AP422 and AP426 by using 125 
conventional methods (Alloing et al., 1998) and transformants were selected using erythromycin 126 
(1µg/ml), analyzed by PCR to confirm the presence of the plasmid, and further investigated for the 127 
presence of the capsule. 128 
 129 
Transmission Electron Microscopy. For ultrastructural analysis of the polysaccharide capsule, 130 
bacterial strains were grown on Columbia agar plates and were prepared following the immune-131 
stabilization method (Jacques & Gottschalk, 1997). Briefly, bacteria were resuspended in 0.5 ml of 132 
PBS pH 7.4 and incubated with 0.1 ml of type 7 antiserum (Statens Serum Institute) for 1 hr at 4°C. 133 
After immune-stabilization, bacterial cells were centrifuged at 2500 g for 10 minutes at 4°C and 134 
fixed in fixation solution containing 2.5 % (v/v) glutaraldehyde, 0.075 M lysine acetate in 135 
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cacodylate buffer (0.1 M, pH 7.0) with 0.075% (w/v) ruthenium red (CR buffer) for 2 hrs at 4°C. 136 
Controls processed using an unrelated antiserum (type 21), or without antiserum stabilization, were 137 
performed simultaneously. All bacterial samples were then washed three times with CR buffer and 138 
post-fixed with 1% (w/v) osmium tetroxide in CR buffer for 1 h at RT. Subsequently, samples were 139 
washed three times with cacodylate buffer, dehydrated through a graded series of ethanol and 140 
embedded in Agar 100 epoxy resin. Ultrathin sections of bacterial samples were placed on formvar-141 
coated copper grids, post-stained with uranyl acetate and lead citrate, and examined with a Philips 142 
208s electron microscope at 80 kV. 143 
 144 
Type 7F capsular polysaccharide detection by high-resolution magic angle spinning NMR 145 
spectroscopy (HR-MAS NMR). Bacteria recovered from THYE were inactivated by 1% v/v 146 
formaldehyde treatment and then washed three times with PBS in deuterium oxide (D2O, Sigma-147 
Aldrich, St. Louis, MO, USA). Approximately 50 µl of compact pellet were inserted in a Kel-F 148 
disposable insert for 50 µl volume and then in a 4 mm MAS ZrO2 rotor (Bruker, Madison, WI, 149 
USA). Proton HR-MAS NMR experiments were recorded by a Bruker Avance III 400 MHz 150 
spectrometer using a Bruker 4-mm HR-MAS probe. The spectra were recorded at 4500 Hz spin rate 151 
and 25°C. The 1H spectra were acquired with the combination of a diffusion filter pulse sequence 152 
with gradient pulses (diffusion filter 85%), to remove the low molecular weight species free in 153 
solution, and a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence [90-(τ-180-τ)n-acquisition] as 154 
T2 filter (76.8 ms), to remove the broad signals of larger molecular species. 5 mg of purified 7F 155 
polysaccharide (Merck & Co., Whitehouse Station, NJ, USA) were solubilized in 0.75 ml of D2O 156 
(D2O, Sigma-Aldrich, St. Louis, MO, USA), the solution inserted in 5-mm NMR tube (Wilmad, 157 
Vineland, NJ, USA) and proton NMR experiment recorded at 25°C by the same spectrometer, using 158 
a 5-mm broadband probe (Bruker, Madison, WI, USA). 1H NMR spectrum was recorded using a 159 
standard one-pulse experiment. Both the solid- and liquid-state NMR spectra were collected with 32 160 
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k data points over a 10 ppm spectral width. The transmitter was set at the HDO frequency, which 161 
was also used as reference signal (4.79 ppm). The TOPSPIN 2.1 software package (Bruker, 162 
Madison, WI, USA) was used for data acquisition and processing of all spectra.  163 
164 
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RESULTS 164 
 165 
S. pneumoniae NT invasive strains AP422 and AP426 contain a 7F capsular locus with point 166 
mutations in wchA. 167 
The two invasive S. pneumoniae strains AP422 and AP426 were defined NT since serotype testing 168 
(confirmed by the Statens Serum Institute, Copenhagen) did not reveal positivity for any capsular 169 
type. In order to verify if these strains belonged to a clonal lineage specifically referable to NT 170 
pneumococci, they were subjected to MLST analysis. Both AP422 and AP426 were ST191, which, 171 
according to a search performed on the S. pneumoniae MLST database (www.mlst.net, accessed on 172 
08.18.2011), is mainly (96%) associated with serotype 7F. Using PCR amplification, 7F cps was 173 
detected in both AP422 and AP426 and then sequenced. Comparison with two reference 7F cps 174 
sequences (GenBank accession numbers CR931643 and ABFT01000009) revealed the presence of 175 
the entire 7F locus with an overall nucleotide identity of 99.8% in both strains. Sequence analysis 176 
highlighted the existence of a distinct single point mutation in the wchA gene in both strains. With 177 
respect to the reference wchA nucleotide sequence, AP422 wchA showed a frameshift mutation due 178 
to the deletion of an adenine in position 910, while AP426 wchA showed a G1081T transvertion, 179 
which creates a new stop codon. Both mutations lead to the formation of a shorter wchA gene 180 
associated with the translation of a protein truncated at the C-terminus (Fig. 1). The NCBI 181 
Conserved Domain algorithm (www.ncbi.nlm.nih.gov/structure/cdd/cdd.shtml) predicts the WchA 182 
catalytic domain to be at the C-terminus of the protein (Fig. 1), so that the truncated WchA proteins 183 
coded by AP422 and AP426 are predicted to be enzymatically inactive. In the polysaccharide 184 
biosynthesis pathway, WchA (also known as CpsE) is the initial glucose phosphate-transferase, 185 
responsible for the linkage of an activated glucose phosphate to the lipid carrier (Pelosi et al., 186 
2005). Since WchA has been demonstrated to be required for the biosynthesis of other capsular 187 
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types (Pelosi et al., 2005), the mutations identified in wchA in both AP422 and AP426 are likely to 188 
be responsible for their non-typeability.  189 
 190 
Over-expression of a functional WchA restores the ability of S. pneumoniae to synthesize the 191 
7F capsule.  192 
With the aim to demonstrate that the mutations present in wchA were sufficient to account for the 193 
lack of capsule in AP422 and AP426, a functional WchA was over-expressed in both NTPn strains. 194 
AP422 and AP426 were transformed with the recombinant plasmid pMU1328_Pc_wchA to 195 
generate the respective recombinant strains AP422∇pMU1328_Pc_wchA and 196 
AP426∇pMU1328_Pc_wchA. The two transformed NTPn yielded a positive reaction with the 7F 197 
antiserum in the Quellung reaction. To confirm that WchA over-expression had restored the ability 198 
to synthesize a capsule at levels comparable to a wild type capsulated strain, the NTPn isolates 199 
along with their WchA over-expressing derivatives were analyzed by TEM and by HR-MAS NMR 200 
using the serotype 7F strain AP425 as a positive control. For TEM analysis, the two NTPn strains 201 
along with AP425 and the WchA over-expressing derivatives were stabilized with type 7 antiserum 202 
before processing for TEM observation. This method was chosen as an alternative of the standard 203 
fixation protocol with lysine and ruthenium red (Kreikemeyer et al., 2011); indeed, the latter 204 
appeared inadequate to visualize the 7F capsule polysaccharide (data not shown) since it does not 205 
contain anionic charged moieties (Moreau et al., 1988). After immune-stabilization a well-206 
preserved dense and thick capsular material was surrounding the AP425 bacterial cells (Fig. 2a), 207 
while non-typeable AP422 (Fig. 2b) and AP426 (Fig. 2c) did not exhibit any characteristic 208 
polysaccharide layer on the surface. In WchA over-expressing AP422 and AP426 (Fig. 2d and 2e) 209 
TEM examination revealed cells surrounded by a capsular polysaccharide structure comparable to 210 
that of AP425, although the capsule of WchA over-expressing AP422 appeared heterogeneous and 211 
in some bacterial cells slightly irregular and thinner. In order to confirm the data obtained by TEM, 212 
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proton HR-MAS NMR spectra directly recorded on inactivated cells in the heterogeneous phase 213 
was performed. 1H NMR spectrum collected on purified polysaccharide in liquid state clearly 214 
revealed specific peaks corresponding to the 7F capsular polysaccharide, such as the anomeric 215 
protons at 5.0÷5.6 ppm and the C6 methyl group of rhamnose at 1.2÷1.4 ppm (Fig. 3a). Spectra 216 
analysis showed the absence of the 7F specific peaks in the two NTPn and in AP422 and AP426 217 
transformed with an empty pMU1328 plasmid (Fig. 3b) while the above mentioned 7F specific 218 
peaks were present both in the capsulated AP425 and in the WchA over-expressing AP422 and 219 
AP426 (Fig. 3b). Although signals of other 1H-NMR sensitive molecules expressed on the bacterial 220 
surface are partially overlapped with the capsular polysaccharide peaks, the anomeric proton at 5.6 221 
ppm and the C6 methyl group of rhamnose at 1.2-1.4 ppm fall in spectral windows without other 222 
peaks and the assignment results certain. 223 
 224 
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DISCUSSION 225 
 226 
It is commonly assumed that NTPn lack the polysaccharide capsule, the principal 227 
pneumococcal virulence factor that acts by protecting the bacteria during the early phase of 228 
infection. Capsule deficiency impairs the capability of NTPn to evade the host's immune defence so 229 
that only rarely these strains are able to persist in the blood and cause invasive disease. The 230 
mechanism by which these strains overcome complement activity and phagocytosis during infection 231 
remains largely unknown. Other pneumococcal structures, such as the surface proteins PspA (Ren 232 
et al., 2003) and PspC (Jarva et al., 2002), are able to inhibit complement activation and deposition 233 
and likely contribute to inhibition of phagocytosis. Indeed, very few cases of invasive diseases due 234 
to NTPn have been reported in large epidemiological studies (Beall et al., 2006).   235 
Hathaway et al. reported that in approximately 30% of naturally occurring NTPn the cps 236 
was present. Non-typeability was assumed to be due to mutations in the cps genes, but sequencing 237 
was not performed and the gene(s) involved remained unknown (Hathaway et al., 2004). 238 
 In this study, we have investigated the molecular basis responsible for non-typeability of 239 
two NT strains isolated from cases of bacteremic pneumonia in the same hospital during the same 240 
year. Molecular analysis of the two invasive NTPn, revealed that these strains were genetically 241 
related, since both belonged to ST191 and carried the 7F cps. However, they presented distinct 242 
point mutations in the wchA gene that were responsible for their non-encapsulated phenotype. wchA 243 
is responsible for the first step of capsule biosynthesis, since it codes for a glycosyltransferase that 244 
catalyzes the transfer of the initial sugar to a lipid acceptor, thus initiating the synthesis of the 245 
capsule repeat units (Pelosi et al., 2005). Both mutations, introducing a premature stop codon in 246 
wchA, are expected to produce a glycosyltransferase truncated in its catalytic domain (Pelosi et al., 247 
2005). Re-establishment of a functional wchA in both NTPn restored the 7F capsule production as 248 
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clearly demonstrated by serotyping, TEM and HR-MAS NMR. HR-MAS spectroscopy appeared as 249 
a powerful methodology to detect the bacterial capsule and to confirm its identity. In fact, although 250 
precise quantification of the polysaccharide capsule content could not be provided due to the 251 
variable number of cells used as input in the analysis, this method clearly gave a semi-quantitative 252 
estimation of the specific polysaccharide expressed on the bacterial surface.  253 
Our report is the first describing naturally occurring wchA mutations responsible for the NT 254 
phenotype in pneumococci. The essentiality of wchA for capsular assembly has previously been 255 
shown in laboratory mutants of other S. pneumoniae serotypes. Insertion-duplication mutagenesis 256 
or introduction of a premature stop codon in wchA made pneumococci of serotype 19F, 14, 9N, 13 257 
and 15B unable to produce the capsule (Guidolin et al., 1994; Kolkman et al., 1996; Kolkman et 258 
al., 1998). Furthermore, sequence duplications within wchA were found to be responsible for 259 
capsular phase variation in sorbarods-generated pneumococci of serotypes 3, 8 and 37 (Waite et al., 260 
2001; Waite et al., 2003).  261 
 This study identified two new point mutations, involving wchA, responsible for the 262 
unencapsulated phenotype in two NTPn isolated from invasive disease, providing evidence 263 
regarding the key role of wchA also in serotype 7F capsule biosynthesis process. This result 264 
suggests that single point mutations represent a mechanism generating NTPn in nature besides the 265 
mechanisms already described such as down-regulation of capsule synthesis or loss of the capsule 266 
biosynthetic locus (Hathaway et al., 2004; Hanage et al., 2006). It is intriguing that two genetically 267 
related strains, isolated from invasive diseases in the same hospital in the same year, underwent 268 
distinct point mutations in wchA, thus affecting the production of a type 7F capsule. The success of 269 
such strains in causing invasive disease might be due to a protection from the immune response 270 
exerted by other virulence factors and/or an immune deficiency of the host. Unfortunately, no data 271 
concerning the immunological status of patients from whom AP422 and AP426 were isolated are 272 
available. Furthermore, it is difficult to argue if the mutations occurred prior or during infection, 273 
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since we do not have serial isolates from the same patient. Extensive analyses on NTPn collections 274 
will ascertain whether wchA is prone to point mutations, leading to the loss of capsule, also in other 275 
NTPn clinical strains and estimate how frequently the single point mutation mechanism is used by 276 
pneumococci to silence capsule expression.  277 
 278 
279 
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FIGURE LEGENDS 416 
 417 
Fig. 1. Alignment of the WchA amino acids sequences of the reference strain 554/62 (GenBank 418 
accession number CR931643) and the two NTPn AP422 and AP426. In both AP422 and AP426 419 
wchA is translated as a C-terminal truncated protein. Bold types indicate the catalytic domain as 420 
predicted by NCBI Conserved Domain; italic types indicate an alternative C-terminus due to a 421 
frame shift in the nucleotide sequence of AP422. 422 
 423 
Fig. 2. Transmission Electron Microscopy (TEM) of S. pneumoniae strains incubated with type 7 424 
antiserum and stained with ruthenium red. (a): AP425 (serotype 7F); (b): AP422 (NT); (c): AP426 425 
(NT); (d): WchA over-expressing AP422 strain; (e): WchA over-expressing AP426 strain. Over-426 
expression of WchA restored capsule production in both AP422 and AP426. 427 
 428 
Fig. 3. Proton NMR spectra of 7F purified polysaccharide and S. pneumoniae strains. (a) Schematic 429 
representation of the chemical structure of 7F polysaccharide. (b) Proton HR-MAS NMR spectra 430 
recorded in heterogeneous phase on inactivated bacterial cells. The presence or the absence of the 431 
capsule on the bacterial surface, based on spectra analysis, is indicated for each strain. Red arrows 432 
indicate anomeric proton at 5.6 ppm, while blue arrows indicate the C6 methyl group of rhamnose at 433 
1.2÷1.4 ppm. 7F purified polysaccharide solubilised in denaturated water is used as a positive 434 
control. 435 
 
 
 
 
 
 
 
554/62  1    MDEKGLKIFLAVLQSIIVILLVYFLSFVREAELERSSMVILYLLHFFVFYFSSYGNNFFKRGYLVEFNSTIRYIFFFAIAISVLNFFIAERFSISRRGMV 
AP422   1    MDEKGLKIFLAVLQSIIVILLVYFLSFVREAELERSSMVILYLLHFFVFYFSSYGNNFFKRGYLVEFNSTIRYIFFFAIAISVLNFFIAERFSISRRGMV 
AP426   1    MDEKGLKIFLAVLQSIIVILLVYFLSFVREAELERSSMVILYLLHFFVFYFSSYGNNFFKRGYLVEFNSTIRYIFFFAIAISVLNFFIAERFSISRRGMV 
 
554/62  101  YFLTLEGISLYLLNFLVKKYWKHVFFNLKNSKKILLLTVTKNMEKVLDKLLESDELSWKLVAVSVLDKSDFQHDKIPVIEKEKIIEFATHEVVDEVFVNL 
AP422   101  YFLTLEGISLYLLNFLVKKYWKHVFFNLKNSKKILLLTVTKNMEKVLDKLLESDELSWKLVAVSVLDKSDFQHDKIPVIEKEKIIEFATHEVVDEVFVNL 
AP426   101  YFLTLEGISLYLLNFLVKKYWKHVFFNLKNSKKILLLTVTKNMEKVLDKLLESDELSWKLVAVSVLDKSDFQHDKIPVIEKEKIIEFATHEVVDEVFVNL 
 
 
554/62  201  PGESYDIGEIISRFETMGIDVTVNLKAFDKNLGRNKQIYEMVGLNVVTFSTNFYKTSHVISKRILDICGATIGLILFAIASLVLVPLIRKDGGPAIFAQT 
AP422   201  PGESYDIGEIISRFETMGIDVTVNLKAFDKNLGRNKQIYEMVGLNVVTFSTNFYKTSHVISKRILDICGATIGLILFAIASLVLVPLIRKDGGPAIFAQT 
AP426   201  PGESYDIGEIISRFETMGIDVTVNLKAFDKNLGRNKQIYEMVGLNVVTFSTNFYKTSHVISKRILDICGATIGLILFAIASLVLVPLIRKDGGPAIFAQT 
 
 
554/62  301  RIGKNGRHFTFYKFRSMRSDAEAIKEQLMDQNTMQGGMFKIDNDPRVTKIGRFIRKTSLDELPQFWNVFIGDMSLVGTRPPTVDEYVQYTPEQKRRLSFK 
AP422   301  RIGKMVDILPFINSVRCGAMLKLSKNS 
AP426   301  RIGKNGRHFTFYKFRSMRSDAEAIKEQLMDQNTMQGGMFKIDNDPRVTKIGRFIRKTSLD 
 
 
554/62  401  PGITGLWQVSGRSKITDFDDVVKLDVAYIDNWTIWKDIEILLKTVKVVFMREGAK 
AP422 
AP426  
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Streptococcus pneumoniae expresses on its surface adhesive
pili, involved in bacterial attachment to epithelial cells and vir-
ulence. The pneumococcal pilus is composed of three proteins,
RrgA,RrgB, andRrgC, each stabilized by intramolecular isopep-
tide bonds and covalently polymerized by means of intermolec-
ular isopeptide bonds to form an extended fiber. RrgB is the
pilus scaffold subunit and is protective in vivo in mouse models
of sepsis and pneumonia, thus representing a potential vaccine
candidate.The crystal structure of amajorRrgBC-terminal por-
tion featured an organization into three independently folded
protein domains (D2–D4), whereas the N-terminal D1 domain
(D1) remained unsolved. We have tested the four single recom-
binant RrgB domains in active and passive immunization stud-
ies and show that D1 is the most effective, providing a level of
protection comparable with that of the full-length protein. To
elucidate the structural features of D1, we solved the solution
structure of the recombinant domain by NMR spectroscopy. The
spectra analysis revealed that D1 has many flexible regions, does
not contain any intramolecular isopeptide bond, and shares with
theotherdomains an Ig-like fold. In addition,wedemonstrated, by
site-directedmutagenesisandcomplementation inS.pneumoniae,
that the D1 domain contains the Lys residue (Lys-183) involved in
the formation of the intermolecular isopeptide bonds and pilus
polymerization. Finally, we present a model of the RrgB protein
architecture alongwith themapping of two surface-exposed linear
epitopes recognized by protective antisera.
Streptococcus pneumoniae is an important human pathogen
responsible for diseases such as otitismedia, pneumonia, sepsis,
and meningitis (1–6). However, S. pneumoniae is also a com-
mon inhabitant of the respiratory tract of children and healthy
adults. This carriage state could represent a risk factor for the
development of respiratory diseases but also the source for
pneumococcal transmission to other individuals (7–9). Like
most streptococci, S. pneumoniae decorates its surface with
long filaments known as pili (10–14). Pneumococcal pili have
previously been associated with virulence and the capability of
the microorganism to adhere better to epithelial cells and to
colonize the nasopharynx (10, 15, 16). The pneumococcal pilus
is a multimeric structure consisting of three proteins (RrgA,
RrgB, and RrgC) polymerized by three sortase enzymes (SrtC1,
SrtC2, and SrtC3) through the formation of covalent intermo-
lecular isopeptide bonds (17–21). In particular, multiple copies
of RrgB are polymerized to form the scaffold of the pilus,
whereas the major adhesin, RrgA, and the putative anchor,
RrgC, are localized at the tip and at the base of the pilus, respec-
tively (15, 22, 23).
Recently, the structure of a major portion of RrgB (residues
184–627) was solved at a 1.6 Å resolution (24) and revealed an
organization into three independently folded IgG-like domains
(D2, D3, and D4, residues 184–326, 326–446, and 446–627,
respectively). On the contrary, the structure of the RrgB N-ter-
minal region (D1, residues 1–184), likely constituting a fourth
independently folded domain, remained unsolved due to the
failure to obtain the crystals of the full-length (FL)3 RrgB (24).
Interestingly, each of the D2, D3, and D4 domains is stabilized
by one intramolecular isopeptide bond. These covalent link-
ages, formed between Lys and Asn residues, have been found in
other pilus proteins (19, 25–28) and are thought to play a role
similar to that of disulfide bonds; they confer in fact a rigid
molecular architecture to the pili and make them less suscepti-
ble to proteolytic cleavage (Fig. 1).
In the pilus backbone assembly RrgB molecules are linked
together by sortases through intermolecular isopeptide bond
formation between a Thr within the C-terminal LPXTG motif
of a molecule and a Lys located at the N terminus of the follow-
ing molecule (18, 26, 29) (Fig. 1). In Corynebacterium diphthe-
riae, where the general principles of pilus assembly were first
* This work was supported byMinistero dell’Istruzione, dell’Universita` e della
Ricerca (Fondi per gli Investimenti della Ricerca di Base-Proteomica
RBRN07BMCT) and Integrated Structural Biology Infrastructure for Europe
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□S The on-line version of this article (available at http://www.jbc.org) contains
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Figs. S1–S6.
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The NMR chemical shifts have been deposited in the BioMagResBank (acces-
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3 The abbreviations used are: FL, full-length; BisTris, bis(2-hydroxyethyl)imi-
notris(hydroxymethyl)methane; cryo-EM, cryoelectron microscopy; cfu,
colony-forming units; HSQC, heteronuclear single quantum coherence;
PDB, Protein Data Bank; r.m.s.d., root mean square deviation; WB, Western
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established, the functional Lys is located within a conserved
YPKN “pilin” motif (18, 27, 30). Nevertheless, this sequence
is not absolutely required for polymerization as demon-
strated by studies on the Spy0128 pilin of Streptococcus pyo-
genes, where the lysine forming the intermolecular isopep-
tide bond and responsible for pilus polymerization is located
into 159GSKVPI164 motif even though the YPKN pilin motif
is also present (26, 31).
RrgB, alongwith the other two pilus proteins RrgA andRrgC,
was previously shown to confer protection in mouse models of
infection and therefore is regarded as a potential candidate for a
new generation of protein-based vaccines (32, 33). We have
investigated the protective ability of the single recombinantD1,
D2, D3, and D4 domains of RrgB in a mouse model of sepsis,
and here we provide evidence that D1 is the most protective,
followed byD4. Furthermore, we present the solution structure
of the recombinant D1 obtained by NMR spectroscopy and
show that Lys-183 of D1 is engaged in the intermolecular iso-
peptide bond formation during pilus polymerization. Finally,
we propose a possible model of the entire RrgB molecule and
show the positions of two linear epitopes possibly involved in
the protection mechanism.
MATERIALS ANDMETHODS
Bacterial Strains and Cultures—For the animal experiments,
the S. pneumoniaeTIGR4 (serotype 4) strain was used. Bacteria
were grown, frozen in aliquots at80 °C, and titrated as already
reported (32). Immediately prior to challenge, frozen aliquots
were thawed and diluted in PBS to reach the working
concentration.
Cloning and Protein Expression and Purification—Standard
recombinant DNA techniques were used to construct the
expression plasmids (pET21b; Novagen) and to express and
purify the recombinant C-terminal His-tagged proteins (for
details, see supplementalMaterials andMethods, and the prim-
ers used are listed in supplemental Table S1). The affinity-pu-
rified proteins were subsequently used to immunize CD1 mice
or rabbits for antibody generation (Charles River Laboratory)
and BALB/c mice to evaluate the protective efficacy.
Complementation Plasmids—Wild-type or mutant rrgB
genes were amplified from chromosomal DNA of TIGR4 strain
by PCR by using the primers listed in supplemental Table S2;
point mutations were introduced by overlap extension PCR by
using specific primers (supplemental Table S2). PCR products
were then cloned into the complementation plasmid pMU1328
between the BamHI and SalI restriction sites (34). Expression of
RrgB or RrgB mutated forms was under control of the erythro-
mycin constitutive promoter (Pc) which was amplified with the
primers listed in supplemental Table S2 and cloned immedi-
ately upstream rrgB (EcoRI, BamHI). All plasmids were con-
firmed by sequencing.
Generation of rrgB Deletion Mutants and rrgB Comple-
mentants—A TIGR4 rrgB isogenic mutant was generated by
allelic exchange. Fragments of 500 bp upstream and down-
stream the target genewere amplified by PCR (oligonucleotides
are listed in supplemental Table S2) and spliced into a kanamy-
cin resistance cassette by using overlap extension PCR; the PCR
fragments were then cloned into pGEMt (Promega) and trans-
formed in S. pneumoniae with conventional methods (35). To
select the bacteria in which the target gene was replaced with
the resistance cassette, bacteria were plated on blood-agar
plates with kanamycin (500 g/ml). The presence of the iso-
genic mutation was confirmed by PCR andWestern blot (WB)
analysis. To obtain RrgB-complemented mutants, pMU1328
plasmids containing WT rrgB or rrgB mutated forms were
transformed into TIGR4 rrgB with conventional methods.
Transformants selection was performed by supplementing
media with kanamycin (500 g/ml) and erythromycin (1
g/ml). The complemented mutants were then analyzed by
PCR; expression of FLWT RrgB or RrgBmutants was detected
by WB analysis of whole cell lysates.
SDS-PAGE and Western Blot Analysis—SDS-PAGE analysis
was performed using NuPAGETM 4–12% BisTris gradient gels
(Invitrogen) according to the manufacturer’s instructions.
Hi-MarkTM prestained HMW (Invitrogen) served as protein
standard. Gels were processed for WB analysis by using stan-
dard protocols. Mouse polyclonal antibodies raised against
recombinant His-tagged RrgB were used at 1/3000 dilution.
Secondary goat anti-mouse IgG alkaline phosphatase-conju-
gated antibodies (Promega) were used at 1/5000, and signals
were developed by usingWestern Blue Stabilized Substrate for
Alkaline Phosphatase (Promega).
Animal Experiments—Animal studies were done in compli-
ance with the current law approved by the local Animal Ethics
Committee and authorized by the Italian Ministry of Health.
Female, 6-week-old, specific pathogen-free BALB/c mice
(Charles River) received three intraperitoneal immunizations, 2
weeks apart. Each dose was composed of 20 g of either the
single RrgB domains or the FL RrgB, or of a combination of the
four RrgB domains (D1D2D3D4), 10 g each, along with
400g of aluminumhydroxide as an adjuvant, in a final volume
of 200 l of PBS. Control animals received the same course of
saline plus adjuvant. Ten days after the third immunization,
samples of sera were obtained from each animal and pooled
according to the immunization group to be used in passive
serum transfer experiment. Two weeks after the third immuni-
zation, each mouse was challenged intraperitoneally with a
mean dose of 1.6 102 cfu of TIGR4. Bacteremia was evaluated
24 h after challenge, andmortality coursemonitored for 10 days
after challenge as already reported (32). The animals were
euthanized when they exhibited defined humane end points
that had been preestablished for the study in agreement with
Novartis Animal Welfare Policies.
FIGURE1.Schematic representationofpilusbackboneproteinRrgB.Pilus
scaffold is composed by multiples copies of RrgB protein in a head-to-tail
arrangement. Pilus polymerizationoccurs through intermolecular isopeptide
bonds (red),whereas eachRrgBprotein is stabilizedby intramolecular isopep-
tide bonds (black). Lys-183 as a residue involved in the intermolecular bond
has been identified in the present work.
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For passive protection experiments, 8-week-old mice were
used. Fifteen minutes before TIGR4 intraperitoneal challenge
(102 cfu/mouse), eachmouse received intraperitoneally 50l of
pooledmouse sera against recombinant D1 or D4, or of control
sera obtained immunizing with adjuvant plus saline.
Statistical Analysis—Bacteremia and mortality course were
analyzed by theMann-WhitneyU test. Survival rates were ana-
lyzed by Fisher’s exact test. One-tailed or two-tailed tests were
used to compare immunized groups with the control group or
each other, respectively. Values of p  0.05 were considered
and referred to as significant. Values of p 0.1 were referred to
as a trend.
Flow Cytometry on Entire Bacteria—TIGR4 were grown in
Todd-Hewitt yeast extract broth to an exponential phase
(A600  0.25), fixed with 2% formaldehyde, and then stained
with pooled mouse antisera raised against FL RrgB or RrgB
domains at 1:400 dilution. Mouse IgG were detected with
FITC-conjugated goat anti-mouse IgG (Jackson Laboratories)
at 1:100 dilution, and bacterial staining was analyzed by using a
FACS-Calibur cytometer (Becton Dickinson). Sera from mice
immunized with PBS plus adjuvant were used as negative
control.
ELISA—96-wellMaxiSorpTM flat-bottomplates (Nunc)were
coated with 0.2 g/well FL RrgB overnight at 4 °C. Plates were
then washed three times with PBS/0.05% Tween 20 and satu-
rated for 1 h at 37 °C with PBS/1% BSA. Following three wash-
ing steps with PBS/0,05% Tween 20, the plates were incubated
for 2 h at 37 °C with serial dilutions of the pooled mouse sera.
After another three washing steps, bound antigen-specific
mouse IgGs were revealed with alkaline phosphatase-conju-
gated goat anti-mouse IgG (Sigma), followed by the phospha-
tase alkaline substrate p-nitrophenyl phosphate (Sigma). The
intensity of color was quantified with an ELISA plate reader at
A405. The antibody titer was expressed as the log10 of the recip-
rocal of the serum dilution that gave A405 1.
PepScan Analysis—Arrayed peptides were synthesized in
situ on glass fiber membranes. Membranes were conditioned
by wetting with ethanol and washing three times for 5 min in
TTBS (50 mM Tris-HCl, pH 7.0, 137 mM NaCl, 2.7 mM KCl,
0.05% Tween 20). After overnight blocking at 4 °C in MBS (2%
drymilk inTTBS),membraneswere incubated for 1.5 h at 37 °C
with polyclonal antisera (1:3000 inMBS) followed by secondary
goat anti-mouse IgG alkaline phosphatase-conjugated antibod-
ies (1:5000 in MBS; Promega), and signals were developed by
usingWestern Blue Stabilized Substrate for Alkaline Phospha-
tase. For image processing, membranes were scanned using an
Epson V750 Pro scanner at 800 dpi, 48-bit color depth andwith
gamma 1.0 full linear response.
NMRCharacterization of RrgB D1 Domain—Expression and
purification of labeled D1 were carried out as described in the
supplemental Materials and Methods. NMR spectra were
acquired at 298 K on Avance 900, 800, 700, and 500 MHz
Bruker spectrometers, all equipped with a triple resonance
cryoprobe. The NMR experiments, used for the backbone and
the aliphatic side chain resonances assignment recorded on
13C/15N and 15N enriched samples or on unlabeledD1 samples,
are summarized in supplemental Table S3. Backbone dihedral
angle constraints were derived from 15N, 13C’, 13C, 13C, and
Ha chemical shifts, using TALOS (36). Distance constraints
for structure determinationwere obtained from 15N-edited and
13C-edited three-dimensional NOESY-HSQC. 3131 meaning-
ful proton-proton distance restraints (supplemental Table S4),
with 114  and 120  backbone dihedral angles restraints were
included in structure calculations. The exchangeability of the
backbone amide hydrogen nuclei with solvent protons was
investigated through a 1H-15N HSQC experiment performed
on a protein sample dialyzed against deuterated buffer for 3
days. Hydrogen bond constraints for the slowly deuterium-ex-
changing amide protons of the -strands were introduced at
later steps of the structure calculations.
Structure calculations were performed through iterative
cycles of CYANA-2.1 (37) followed by restrained energy mini-
mization with the AMBER 10.0 Package in explicit water sol-
vent (38). The quality of the structures was evaluated by using
the iCING validation program (for details, see supplemental
Table S4). The program MOLMOL was subsequently used for
structure analysis (39).
The final bundle of 20 conformers ofD1has an average target
function of 1.36 0.13 (CYANA units). The average backbone
r.m.s.d. value (over residues 28–183) is 0.71  0.19Å, and the
all-heavy atoms r.m.s.d. value is 0.96  0.16. Per-residue
r.m.s.d. values are shown in supplemental Fig. S1.
Heteronuclear Relaxation Data—The dynamic properties of
D1 have been characterized experimentally through 15N relax-
ation measurements. 15N longitudinal and traverse relaxation
rates (40) and 15N{1H}NOEs (41) were recorded at 298 K at 500
MHz, using a protein concentration of 0.8 mM.
The average backbone 15N longitudinal R1 and transversal R2
relaxation rates and 15N{1H} NOE values are 1.45  0.1 s1,
16.18  1.5 s1, and 0.71  0.04, respectively (supplemental
Fig. S2). They are essentially homogeneous along the entire
polypeptide sequence, with the exception of residues located at
the C and N termini and three loop regions (56–69, 148–162,
and 173–177). The correlation time for the molecule tumbling
(c), as estimated from the R2/R1 ratio, is 11.49  1.9 ns, con-
sistent with themolecular mass of themonomeric protein. The
relaxation data were analyzed according to the model-free
approach of Lipari and Szabo (42, 43) using TENSOR2 (44)
(supplemental Fig. S2).
Rigid Body Fitting—Theprocedure used to accommodate the
NMR D1 structure into the EM map of the whole pilus previ-
ously generated (24) followed the same procedures used for the
fitting of the RrgBD2-D4 x-ray crystal structure and the D1
computer model into the EM pilus map (22). A preliminary
rigid body fitting of theD2–D4 crystal fragment was performed
by using CHIMERA (45–47) followed by a rigid body fitting of
the D1 NMR coordinates into the leftover N-terminal apical
volume of the pilus. The D1 NMR coordinates were first fitted
manually using CHIMERA by placing as much of the atomic
structure as possible into the EMdensitymap, approximately in
the position thought to be correct. This step was then followed
by a rigid-body fitting using the “fit model in map” tool from
CHIMERA. This tool calculates, for the selected atoms, a posi-
tion that maximizes locally the sum of the densities. The eval-
uation of the correlation coefficient values, the resulting aver-
agemap value at the fit atoms, the number of fits atoms outside
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the lowest value contour surface displayed were the parameters
used to assess the fit of the D1 molecule.
RESULTS
Distinct Domains of RrgB Provide Protection in Active Immu-
nization Experiments—The protective efficacy of each of the
four RrgB domains or of a mixture of them was assessed in a
mouse model of intraperitoneal challenge (TIGR4) in two dis-
tinct experiments, performed under the same conditions,
which were combined to reach n  13–16 mice/group. The
results are summarized in Fig. 2,A andB, and detailed statistical
analysis is provided in supplemental Table S5A.
All RrgB domains except D3 afforded significant protection
against bacteremia (Fig. 2A), giving a reduction of the cfu geo-
metric mean by 1–2 logs with respect to the controls. These
values were similar to those afforded by the FL RrgB and by the
combination of the four domains D1D2D3D4. The
results of mortality are reported in Fig. 2B and supplemental
Table S5A. D1 and D4 conferred significant increase of
survival time, similar to FL RrgB and the combination
D1D2D3D4. In particular, themedian survival for the D1
groupwas 2.5 days higher respect to that of the control group (4
versus 1.5 days). At the end of the mortality observation, a sig-
nificant survival rate was found forD1 (44% survival), D4 (27%),
FL RrgB (44%), and D1D2D3D4 (31%) groups.
N-terminal D1 Domain Is the Most Protective in Vivo—
Among the single RrgB domains, D1 andD4 showed themost
significant protective efficacy and were therefore analyzed
further in a larger group of mice. Four different experiments,
carried out under the same conditions, were combined to
FIGURE 2. RrgB domains are protective in active immunization experiments. A and C, bacteremia. Circles represent the log cfu/ml of blood for individual
animals; horizontal bars represent themean value of the log cfu/ml S.E. for the group; the dotted linemarks the detection limit (values under the dotted line
correspond to animals inwhich no cfuwere detected). The treatment groups are indicated on the bottom. B andD, survival. The survival course for each group
is represented. The treatment groups are indicated close to each of the corresponding survival lines. A and B, n 13 for D2 group, 15 for D4 and control (alum
ctrl) groups, 16 for the remaining groups. C and D, n 31 for each of the groups. ***, p 0.001; **, p 0.01; *, p 0.05.
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reach n 31 animals/group. The results are shown in Fig. 2,
C and D, and detailed statistical analysis is provided in sup-
plemental Table S5B. In terms of bacteremia (Fig. 2C), both
D1 and D4 afforded highly significant protection, with a cfu
geometric mean by 2.6 and 1.5 logs lower, respectively, than
that of the control group, and 8 animals from the D1 group in
which cfu were undetectable. The reduction of bacteremia
was significantly superior in D1 than in the D4 group.
In terms of mortality course (Fig. 2D), both D1 and D4 con-
ferred significant protection. The increase of survival time
afforded by D1 showed a better trend than that of D4. In par-
ticular, only for the D1 group was the median survival time
higher than that of the control group (7.5 versus 1.5 days). At
the end of the mortality observation, the D1 group showed the
highest survival rate, i.e. 45% versus 21% observed for D4. An
evident difference of survival rates between D1 and D4 groups
was observed.
The possible relevance of antibodies in the protection elic-
ited by D1 and D4 was investigated by a passive serum transfer
experiment, with groups of 8mice. The results are shown in Fig.
3, and detailed statistical analysis is provided in supplemental
Table S5C. Both anti-D1 and anti-D4 sera elicited significant
protection against bacteremia (Fig. 3A), with cfu geometric
means lower by 2.6 and 1.6 logs, respectively, than that of the
control group. Only anti-D1 serum afforded significant protec-
tion against mortality, giving 100% survival rate, whereas
santi-D4 gave a protective trend, with 60% survival rate. These
results indicate that immunization with D1 domain and at a
lower extent D4 domain, elicits functional antibodies that may
play a role in the protection.
D1 and D4 Antisera Recognize the Native Pilus and Linear
Epitopes within RrgB—To investigate the differences in protec-
tive efficacy exerted by the isolated RrgB domains with respect
to the FL RrgB in the in vivo assays, mouse sera were tested
for their capability of recognizing the native pilus and the
recombinant FL RrgB. Sera were probed against entire TIGR4
bacteria by FACS analysis. Sera raised against D1, D4, and
D1D2D3D4 gave a fluorescence intensity comparable
with that obtainedwith anti-FL RrgB, whereasD2- andD3-spe-
cific antisera recognized the native pilus less effectively. To
explain the lower recognition efficacy observed with D2 and
D3, the same sera were titrated in ELISA against the recombi-
nant FLRrgB. As shown in supplemental Fig. S3, antibody titers
elicited by D2 and D3 immunization toward FL RrgB were
about 10 times lower than those obtained by immunization
with D1, D4, D1D2D3D4, and FL RrgB, consistent with
the results obtained by FACS analysis on the polymerized
native RrgB.
To gainmore insights on the epitopes recognized by the pro-
tective D1 and D4 polyclonal antibodies, a PepScan approach,
suitable for identifying linear epitopes, was applied. Overlap-
ping 15-mer peptides with an offset of 5 residues were synthe-
sized in situ on a glass fiber membrane. The library of peptides
tested covered residues 25–190 of D1 and 444–628 of D4.
Incubation with the anti-D1 serum (previously used in passive
protection experiments) revealed a single linear epitope cover-
ing residues 40–59 (D1-1) (Fig. 4B), whereas anti-D4 serum
detected a unique linear epitope (D4-1) spanning residues 494–
508 (Fig. 4C).
Solution Structure of theD1Domain—The solution structure
ofD1was investigated byNMRspectroscopy. Its 1H-15NHSQC
spectrum showed well dispersed resonances indicative of an
overall well folded protein (supplemental Fig. S4). D1 showed a
common IgG-like  sandwich fold (41 Å 48 Å 30 Å) and a
topology of secondary structure elements drawn in Fig. 5. The
core of the structure was formed by seven parallel and antiparallel
-strands: 1(36–39), 4(80–85), 7(119–121), 8(127–130),
9(138–143), 10(166–169), and 11(178–180). These -strands
were arranged in two sheets (comprising1,8,11 and4,7,9,
10, respectively) packed against each other and flanked by two
longsegments (40–78, 87–117) locatedbetweenstrands1 and4
andstrands4 and7, respectively.An-helix (49–57), flankedby
two short -strands 2 (42–44) and 3 (73–75), was inserted
within the first segment.Twoadditional-strands5 (89–91) and
6 (97–101) formed a-hairpin structure inserted within the sec-
FIGURE3.Anti-RrgBD1andD4seraareprotective inpassive serumtrans-
fer experiments. Symbols are described in the Fig. 2 legend. n 8 for each of
the groups.
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ond segment. In 50% of 20 conformers of the D1 family an addi-
tional -sheet was formed by two short hydrogen-bonded
-strands (stretches 161–163 and 184–187).
The structure was well defined with the exception of three
long loops corresponding to the stretches 56–69, 148–162,
and 173–177 (supplemental Fig. S1). Heteronuclear relaxation
measurements revealed that residues in the first two loops had
heteronuclear NOE and longitudinal R1 values lower and
higher than average, respectively (supplemental Fig. S2). This
behaviorwas a consequence of local internalmotions occurring
on a faster time scale with respect to the overall reorientational
correlation time (r) of the molecule and accordingly, a corre-
lation time (e) for these fast motions can be fitted for the pre-
vious mentioned loops (supplemental Fig. S2). In addition,
conformational exchange processes, occurring on the millisec-
ond-microsecond scale, affected some residues located in the
region 155–164, as monitored by transverse R2 relaxation rates
higher than the average (supplemental Fig. S2). These data indi-
cated that these loops experience higher flexibility, showing
accordingly a low number of long ranges 1H-1HNOEs (supple-
mental Fig. S5). For a few residues, the assignment of the back-
bone resonances was also not achieved (Glu-143, His-145, Ser-
146, Ser-148, Thr-149, Tyr-150, Val-152, andGly-160), likely as
a consequence of an increased localmobility. The loop between
strands9 and10 (residues 148–162)was themost disordered,
with a r.m.s.d. value of about 2 Å (supplemental Fig. S1). Con-
formational exchange processes on the millisecond-microsec-
ond time scale are observed also for the loop between strands
10 and 11 comprising residues 174–178.
The protein core is characterized by hydrophobic interac-
tions between residues located on the first (strands 1, 8, 11)
and second (strands 4, 7, 9, 10) sheets. A salt bridge
between two complementarily charged side chains of residues
Lys-41 and Glu-143 was also present. The aliphatic side chains
of residues Met-48, Ile-52, Ala-53, and Leu-56, all located on
one side of the -helix, formed hydrophobic interactions with
FIGURE 4. Polyclonal antibodies raised against D1 and D4 recognize the native pilus and linear epitopes within RrgB efficiently. A, TIGR4 bacteria were
incubated with mouse primary antibodies directed against the specified recombinant proteins (1:400 dilution) followed by FITC-conjugated goat anti-mouse IgG
(1:100dilution). Bacterial stainingwasanalyzedby flowcytometry (FACS-Calibur).Mouse control sera (immunizedwithPBSplus alum)wereusedasnegative control.
B andC, glass fibermembraneswith arrayedpeptides synthesized in situ covering residues 25–190 (D1) and444–628 (D4) of RrgBwere incubatedwith anti-D1 (A) or
anti-D4 (B) polyclonal mouse antibodies (1:3000) and then with goat anti-mouse IgG alkaline phosphatase-conjugated antibodies (1:5000). Linear epitopes corre-
sponding to peptide sequences recognized by the antibodies are reported.Underliningmarks common residues present in adjacent peptides in the PepScan.
FIGURE 5. Solution structure of the D1 domain. A, ribbon diagramwith the
secondary structure elements.-Strands are shown in cyan, the-helix in red.
B, topology diagram. The -helix is represented by a red cylinder, and the
-strands are cyan arrows.
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aliphatic residues of2 and3 strands; these interactions deter-
mined the position of the helix with respect to the rest of the
protein.
A search for related protein structures performed through
the DALI Server (48) retrieved the N-terminal domain of the
SpaA pilus backbone protein of C. diphtheriae (Protein Data
Bank (PDB) code 3HTL; r.m.s.d. 2.1 Å), the C-terminal CNA3
domain of themajor pilin protein of Bacillus cereus BcpA (PDB
code 3KPT; r.m.s.d. 2.4 Å), and the N1 domain of the Strepto-
coccus agalactiaeminor pilin GBS52 (PDB code 2PZ4; r.m.s.d.
3.4 Å). Like D1, none of these domains contained intramolecu-
lar isopeptide bonds.However, only the SpaAdomain is located
at the N terminus of pilus backbone protein as D1; their overlay
is presented in Fig. 6A.
In an attempt to determine the orientation ofD1with respect
to the D2–D4 RrgB portion, a rigid body fitting of all the
domains into the shape of the native pilus obtained from cryo-
electronmicroscopy (cryo-EM)was attempted (24). Initial rigid
body fitting of the D2–D4 crystal structure into the cryo-EM
density map of the native pilus left an apical unoccupied vol-
ume, likely due to the absence of D1. However, when the simul-
taneous fitting of the D1 and the D2–D4 domains was carried
out, some portions of D1 could not be accommodated into the
apical empty volume (supplemental Fig. S6 and supplemental
Table S6). To model the FL RrgB, we merged the D1 and
D2–D4 structures into a single molecule by overlapping resi-
dues 188–191, shared by the C terminus of D1 and the N ter-
minus of D2–D4. The relative orientation of D1 with respect to
the others domains was then varied to best fit into the cryo-EM
map (Fig. 6B). The finalmodel, which represents only one of the
possible orientations of D1 with respect to the rest of the pro-
tein, does not present steric clashes betweenD1 and theD2–D4
domains. The two linear epitopes, previously identified to be
locatedwithin theD1 andD4 domains by peptide hybridization
with specific protective polyclonal antibodies (Fig. 4), when
mapped onto the FLmodel of RrgB, confirmed their superficial
localization (Fig. 6B).
Lysine 183 of D1 Is Required for Intermolecular Isopeptide
Bond Formation and Pilus Polymerization—Pili of Gram-posi-
tive bacteria are polymerized by means of intermolecular iso-
peptide bonds occurring between the Thr of the C-terminal
LPXTG motif of a RrgB molecule and a Lys located at the N
terminus of the following molecule (18, 29, 30). To identify the
Lys implicated in the intermolecular isopeptide bond forma-
tion between two consecutive RrgB monomers, a TIGR4 RrgB
deletion mutant (no longer able to assemble a pilus on its sur-
face) was created. Subsequently, RrgB expression and pilus
polymerization were restored in TIGR4RrgB by transforming
the mutant with plasmids expressing either wild-type RrgB or
RrgB mutated in single Lys residues (Lys3 Ala substitutions).
Sequence analysis revealed that the D1 contains the canonical
181YPKN184 pilin motif, with Lys-183 nicely superimposing
onto the functional SpaA Lys-190, as shown in Fig. 6A.
Noteworthy, D1 also presents the sequence fragment
160GSKAVP165, similar to the motif containing the Lys residue
functional for the pilus assembly in S. pyogenes Spy0128 (31).
Lys-183 and Lys-162, along with two additional Lys residues
(Lys-138 and Lys-309), located on D1 and D3 domains, respec-
tively, were selected and mutated.
WB analysis performed on whole cell bacterial lysates using
rabbit polyclonal antisera raised against RrgA, RrgB, or RrgC
revealed that all of the pilus proteins were expressed in all of the
complemented mutants (Fig. 5). However, the typical pilus-as-
sociated high molecular weight ladder was revealed only in the
case of TIGR4RrgB complemented with RrgB wild type or
RrgB mutated in Lys-162, Lys-138, or Lys-309. In contrast, in
the mutant complemented with K183A, RrgB was detectable
only as a monomer (Fig. 7), clearly indicating that Lys-183
is the residue implicated in intermolecular isopeptide bond
formation.
Moreover, in the presence of the RrgB K183A substitution
only hetero-oligomers composed of RrgA-RrgC (about 160
kDa) or RrgB-RrgC (about 110 kDa) could be detected by WB
analysis (see arrows in Fig. 7, A and C). The absence of RrgA-
RrgB heterodimers suggests that RrgA and RrgB are linked
exclusively through intermolecular isopeptide bonds involving
the D1 residue Lys-183 of RrgB.
DISCUSSION
Ever since their initial discovery, pili of Gram-positive bacte-
ria have received considerable attention because they are asso-
ciatedwith a number of different virulencemechanisms (15, 16,
33) and elicit protection in animal models (32, 49–52). In par-
ticular, the S. pneumoniae pilus was found to be implicated in
the initial attachment to epithelial cells (15, 16, 33), and the
pilus components, being protective in mouse models of infec-
tion, are regarded as potential vaccine candidates (32, 33). The
major pilin RrgB is organized into four Ig-like domains (D1–
D4), as shown by combined structural approaches (Ref. 24 and
this work). We have tested the four RrgB domains in animal
model experiments and have shown that the protective efficacy
exerted by the combination of the four RrgB domains
D1D2D3D4 is comparable with that afforded by the FL
FIGURE 6.Analysis of RrgB linker flexibility through superimposition and
modeling. A, superimposition of the D1 domain (blue) and the C. diphtheriae
SpaA N-terminal domain (red). The position of Lys-190 residue, forming the
intermolecular isopeptide bond between two neighboring SpaA molecules,
is shown along with residue Lys-183 of RrgB, which occupies a similar posi-
tion, and is indicated in a black circle. The missing loop in the SpaA crystal
structure is indicated as a gray dotted line. B, modeled conformation of the
full-length RrgB molecule obtained by combining the D1 NMR coordinates
with the RrgB D2-D4 x-ray coordinates. D1-1 and D4-1 epitopes (residues
40–59 and 494–508 respectively) are rendered as yellow spheres.
Protective RrgB D1Domain Involved in Pilus Polymerization
14594 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 16•APRIL 22, 2011
 at N
ovartis G
lobal, on O
ctober 31, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
RrgB.Among the single domains,D1 is themost protective, and
D4 retained an important part of the protective efficacy of the
FL protein. The lower protection achieved by D2 and D3 com-
pared with the FL protein, as well as with the D1 and D4, is
probably because the antibodies elicited by the former two
domains recognize the FL protein less efficiently, in both its
native and recombinant forms.
This may be the result of smaller exposed surface areas expe-
rienced byD2 andD3 in the FLRrgB comparedwith theD2 and
D3 isolated domains and with D1 and D4. It is possible, in fact,
that the antibodies generated against the isolated domains are
recognizing areas of D2 and D3 that are buried in the FL pro-
tein. Alternatively, D2 and D3 could assume a slightly different
conformation when expressed as single domains, thus generat-
ing nonfunctional antibodies. On the other hand, the two linear
epitopes (Fig. 6B) identified withinD1 andD4 by PepScan anal-
ysis performed with protective polyclonal antibodies raised
against the two domains (conformational epitopes are not
detectable with this method) are well exposed on the surface of
the RrgBmolecule and could contribute to the protective activ-
ity exerted by D1 and D4. Further experiments are needed to
understand to what extent these linear epitopes contribute to
the protective activity exerted by the two domains. Taken
together, these results suggest that RrgB contains multiple pro-
tective epitopes, thus confirming the potential of this vaccine
candidate. Furthermore, although the existence of possible
conformational epitopes involving residues from different
domains cannot be excluded, their contribution to the overall
protective efficacy might not be essential.
To obtain more information about the structural role of D1
and to try to correlate it with the protection data discussed
above, we solved the solution structure of this domain by using
NMR spectroscopy. D1 shows an Ig-like fold, does not contain
any intramolecular isopeptide bond, and has many flexible
regions. The observed D1 flexibility, indeed, could play a fun-
damental role in the specific antigen-antibody recognition
process (53), thus accounting forD1 enhanced protection capa-
bility with respect to the more rigid D2–D4 domains, each one
containing an intramolecular isopeptide bond. In fact, the pro-
tein structural plasticity could be related to the ability of D1 to
undergo local conformational changes and to adapt its struc-
ture to optimize the interactions with the antibodies and
increase the affinity and the specificity of the antigen-antibody
recognition process. The dynamics of D1 could therefore
strongly contribute to the interface adaptation for molecular
recognition such that the antibody can select an optimal con-
former from a wide distribution of possible D1 conformations.
The rigid structure of theD2–D4 region prevents such an effec-
tive conformational selection for these domains. The above
described phenomenon has been observed for other protein-
protein or protein-DNA interaction processes (53, 54).
To shed light on the molecular mechanism driving pilus
polymerization in S. pneumoniae, we investigated which of the
lysine residues of D1was engaged in the intermolecular isopep-
tide bond formation. Site-directed mutagenesis followed by
complementation identified Lys-183 as crucial for the pilus
assembly. This result is consistent with the observation that the
spatial position of RrgB Lys-183 can be superimposed onto Lys-
190 of the C. diphtheriae pilus backbone subunit SpaA, known
to be involved in the intermolecular isopeptide linkage (30).
Interestingly, as shown in Fig. 6A, both lysines are not fully
available to form an external bond. In particular, the average
relative solvent accessibility of the Lys-183 over theD1 family of
conformers is 27.2% 4.8, as the Lys side chain projects into a
cleft between the main body of the protein and the segment
40–78 containing the mobile loop 56–69 (27). This suggests
that pilus backbone proteins, to be polymerized,might undergo
conformational changes, probably involving not only the Lys
residue (Lys-183) but also the flexible regions spatially close to
it (49–69, 152–167, and 183–193), to allow the formation of
the covalent intermolecular isopeptide bond. NMR mobility
data indicate that the C terminus of the D1, where Lys-183 is
located, and other loops are highly mobile and that such
dynamics could be relevant for the intermolecular isopeptide
bond formation (supplemental Fig. S2). Consistently, the
absence of stabilizing intramolecular isopeptide bonds renders
D1, unlike the other domains, less rigid and prone to conforma-
tional rearrangements. Furthermore, the occurrence of a struc-
FIGURE 7. Lys-183of RrgB is implicated in intermolecular isopeptidebond formation.WBanalysis was performedusing polyclonal rabbit antisera against
RrgA (A), RrgB (B), and RrgC (C). In all panels lanes are loaded as follows: 1, T4 WT; 2, T4RrgB; 3, T4RrgBRrgBWT; 4, T4RrgBRrgB(K138A); 5,
T4RrgBRrgB(K162A); 6, T4RrgBRrgB(K183A); 7, T4RrgBRrgB(K309A); 8, T4RrgBpMU1328; 9, molecular mass marker. *, RrgA monomer (estimated
molecular mass of native monomeric RrgA is 92 kDa). **, RrgB monomer (estimated molecular mass of native monomeric RrgB is 65 kDa). Arrows, the band
migrating at an apparent molecular mass of 160 kDa indicated by an arrow in lane 2 and 6 of A, and C is compatible with an RrgARrgC complex; the band at
110 kDa present in lane 6 of B and C could correspond to an RrgCRrgB complex.
Protective RrgB D1Domain Involved in Pilus Polymerization
APRIL 22, 2011•VOLUME 286•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 14595
 at N
ovartis G
lobal, on O
ctober 31, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
tural rearrangement of D1 within the native pilus structure is
also in line with the partial fitting of its NMR structure onto the
molecular shape of the native pilus determined by cryo-EM.
Mutagenesis and complementation data were used to ana-
lyze the covalent links established among the three pilus pro-
teins either in the absence of RrgBor in the presence of theRrgB
K183A mutant, in an attempt to provide further insights into
the possible organization of the native pilus. In the presence of
the nonpolymerizing RrgB K183A mutant, the lack of RrgA-
RrgB heterodimers provides evidence that RrgA and RrgB are
unidirectionally linked only through the Lys-183 of RrgB and
the C-terminal Thr of RrgA. This arrangement is in accordance
with the model proposed by Hilleringmann et al., positioning
RrgA at the pilus terminus, thus ruling out the alternative pos-
sibility of RrgA being incorporated along the pilus shaft (22).
Conversely, an RrgA-RrgC multimer is detectable either when
RrgB is not expressed, as already reported by Falker et al. (20)
and LeMieux et al. (55), or in the presence of nonpolymerizing
RrgB K183A. In this case, the mutated RrgB is competing with
RrgA for the linkage to RrgC, as demonstrated by the presence
of RrgB-RrgC hetero-oligomers (Fig. 7, B and C). Concomitant
detection of RrgA-RrgC hetero-oligomers even under these
conditions further strengthens the idea that in wild-type bacte-
ria, although not detectable by electron microscopy analysis of
purified pili, a fraction of RrgA and RrgC might be directly
linked to each other.
In conclusion, this study provides additional information
elucidating pilus proteins features and also paves the way to the
rational design of new RrgB-based molecules to implement a
protein-based vaccine against pneumococcal disease. More-
over, the newly acquired structural and dynamic information
on the RrgB molecule provided by this study suggests that the
conformational flexibility of D1 is pivotal for the protein-anti-
body recognition process. These findings togetherwith the new
functional information could be used to better understand pilus
functions and its role in pathogenesis.
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Abstract
We evaluated the distribution of the two known Streptococcus
pneumoniae pilus encoding islets (PI-1 and PI-2) among a panel of
113 acute otitis media clinical isolates from Israel. PI-1 was present
in 30.1% (n = 34) of the isolates tested, and PI-2 was present in
7% (n = 8). In addition, we found that: (i) the PI positive isolates,
50% of which belong to the international clones Spain9V-3 (ST156)
and Taiwan19F-14 (ST236), correlate with the genotype (as deter-
mined by multilocus sequence typing) but not with the serotype;
(ii) PI-2 was not present in the absence of Pl-1; and (iii) the
frequency of PI-1 was higher among antibiotic-resistant isolates.
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The human pathogen Streptococcus pneumoniae is commonly
associated with invasive diseases such as meningitis and
sepsis. In addition, pneumococci are the most frequent cause
of upper respiratory infections such as sinusitis and acute
otitis media (AOM), which is one of the most widespread
childhood infections and a major cause of morbidity in chil-
dren [1,2]. Hence, it is important to investigate the presence
of pathogenic factors that may be responsible for disease
outcome among AOM clinical isolates.
Recently, genetic analysis of S. pneumoniae clinical isolates
demonstrated that they harbour pilus structures encoded by
the rlrA pathogenicity islet (pilus islet-1, PI-1) and the pilus
islet-2 (PI-2). The PI-1 pilus was shown to be involved in
virulence [3,4] and antibodies raised against its protein
subunits were protective in a murine model of infection [5].
However, the islets are not widely distributed in S. pneumo-
niae. Three independent studies demonstrated that, in both
invasive and nasopharyngeal clinical isolates, the frequency
of the PI-1 islet is approximately 30% [6–8], although the
incidence was higher among antibiotic-resistant clones [8].
This suggests that the interplay between the pilus (encoded
by PI-1) and antibiotic resistance may facilitate the global
spread of antibiotic nonsusceptible pneumococci [9]. A
recent study demonstrated that PI-2 is present in approxi-
mately 16% of invasive and nasopharyngeal clinical isolates
[10], and that both islets are present in the Taiwan19F-14
(ST236) clone, whose spread is responsible for the increas-
ing incidence of antibiotic-resistant isolates in many coun-
tries [11–13].
Therefore, to evaluate a possible correlation between
AOM and the presence of PIs, we aimed to assess the preva-
lence of the pilus encoding islets in a collection of AOM clin-
ical isolates, for which no data are available thus far.
A total of 113 pneumococcal isolates were obtained from
the middle ear fluid of 113 patients with AOM presenting at
the Soroka University Medical Center Pediatric Emergency
Department, from 1 January 2007 to 29 March 2007. The
patients were Jewish children (n = 55) and Bedouin children
(n = 58) who did not receive the heptavalent conjugate
pneumococcal vaccine (PCV7) because PCV 7 vaccination
was not implemented in Israel at the time of the study. The
age of the children was in the range 0.8–96.9 months
(mean ± SD 13.3 ± 15.5 months; median 9.7 months). Of
the 113 isolates, 85 (75%) were obtained by tympanocentesis
and 17 (15%) were from spontaneous drainage; it was not
clear whether the remaining 11 isolates (10%) were obtained
from tympanocentesis or spontaneous drainage. Of 107 iso-
lates from which information about antibiotic treatment of
the patient in the month prior to culture was available, 32
(30%) were from children receiving antibiotics in previous
months. S. pneumoniae was isolated as a single pathogen in
62/113 (65%) cases; in 46 (41%) together with Haemophilus
ª2010 The Authors
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influenzae; and in five (4%) together with other combinations
of pathogens. Identification, serotyping and antimicrobial
susceptibility testing was performed as described previously
[14].
The most commonly isolated serotype was serotype 14,
followed by 19F, 23F, 19A, 6B and 18C (Fig. 1a). All isolates
were tested for the presence of PI-1 and PI-2 by PCR using
a specific set of primers as described previously [8,10].
Amplifications to determine the genomic location and the
presence of islets were performed directly from bacterial
colonies grown overnight on blood-agar plates.
Of 113 isolates, 34 (30.1%) were positive for S. pneumo-
niae PI-1 and eight (7%) were positive for PI-2; PI-1 was
found in serotypes 6A, 6B, 14, 19F, 23F, 33A and 11A,
(Fig. 1a). On the other hand, PI-2 was only found in serotype
19F isolates and always associated with PI-1 (Fig. 1a). Subse-
quently, the isolates containing PI-1 or both PI-1 and PI-2
were typed by multilocus sequence typing [15] and grouped
by E-BURST analysis (http://eburst.mlst.net/) by clonal com-
plex (CC) (Fig. 1b), revealing that they belonged to CCs
already reported to be most likely to carry the PI-1 [6–8].
Isolates that harboured both pilus islets were mainly of the
CC271, single or double locus variants of the international
clone Taiwan19F-14. Among the isolates containing only PI-1,
CC156 was the prevalent clone (international clone Spain9V-3).
Interestingly, out of 12 CC156 isolates, 11 (92%) were sero-
type 14, confirming the increasing association of this sero-
type with clone CC156 [9].
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FIG. 1. Acute otitis media (AOM) isolates collection characterized for the presence of pilus islet (PI)-1 and PI-2. (a) Collection of AOM isolates
stratified by serotype and analysed for the presence of PI-1 and PI-2. *Serotypes with two isolates only (3, 4, 8, 15B, 16F, 18A, 33A) or one iso-
late only (7B, 9N, 9V, 11A, 23A, 23B, 24F, 31, 33F, 35B, not typable). PI-1 was present only in one of the two serotype 33A isolates and in the
11A isolate. (b) PI-1 and PI-2 positive isolates stratified by clonal complex (CC), determined by E-BURST grouping, after multilocus sequence
typing. The serotypes to which the CCs are associated are shown with different colours. CCs have been named according to the sequence
typing number of the E-BURST predicted founder. S, singletons. *Serotype 19F isolates positive for both PI-1 and PI-2.
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No correlation was found with age or gender of the chil-
dren, whereas the percentage of PI positive isolates among
the Jewish population was higher (43.6%) compared with
to Bedouins (17.2%), although the proportion of antibiotic
resistant clones was comparable in the two groups. More-
over, children who had experienced one or more otitis
media episodes in the previous year were more likely to be
infected with S. pneumoniae carrying the pilus-encoding islets
than children who had not (46% vs. 18%; p 0.002). The con-
comitant presence of H. influenzae in the infection site did
not correlate with PIs positive S. pneumoniae (28%).
Because PI-1 was found mainly in serotypes with prevalent
antibiotic resistance, we analysed its presence or absence by
the antibiotic-resistance pattern in each of the serotypes in
which it was described (Table 1). The percentage of PI-1
positive isolates among antibiotic-resistant strains reached
41.5% in penicillin-nonsusceptible isolates (MIC >0.1 mg/L),
51.8% among multidrug-resistant isolates, and 51.6% in eryth-
romycin- resistant isolates. By contrast, the proportion of
PI-1 strains in strains susceptible to all tested antibiotics was
5.7% (p 0.001). These findings confirm the previously found
association between piliated S. pneumoniae and antibiotic
resistance [8].
In conclusion, the data obtained in the present study indi-
cate that the incidence of piliated pneumococci in otitis
media isolates is not greater than in other invasive disease
isolates and that the pilus does not appear to confer an addi-
tional selective benefit in the middle ear during otitis media.
A limitation of the present study is the small sample size of
clinical isolates tested. However, the results obtained con-
firm the correlation of PI in S. pneumoniae with genotype and
antibiotic resistance. Further studies are needed to under-
stand the epidemiological relevance of the pilus and its role
in disease outcome. Although vaccination with PCV7
reduced the frequency of persistent and recurrent AOM
[16], multidrug-resistant nonvaccine serotypes such as sero-
type 19A are increasing, associated with CC156 [17]. This
clone was a prevalent clone in the present study. Therefore,
the elucidation of the pathogenesis of AOM may help
advance the development of a serotype-independent pneu-
mococcal vaccine for otitis media, and a new generation pro-
tein vaccine that includes pilus subunits could reduce otitis
media disease.
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Modified sequential multiplex PCR for
determining capsular serotypes of invasive
pneumococci recovered from Seville
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2) Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del
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Abstract
The heptavalent pneumococcal vaccine’s introduction resulted in
a decline in invasive disease caused by Streptococcus pneumoniae,
but was accompanied by an increase in non-vaccine serotypes.
We evaluated a modified scheme of the sequential multiplex
PCRs adapted to the prevalence of serotypes in Seville (Spain)
for determining capsular serotypes of S. pneumoniae invasive clin-
ical isolates. In adults, the modified scheme allowed us to type
73% with the first three reactions, and 92% with two additional
PCRs. In paediatric patients, it allowed us to type 73.5% with
the first three reactions, and 90% with the two additional PCRs.
The multiplex PCR approach was successfully adapted to target
the serotypes most prevalent in Seville.
Keywords: Capsular polysaccharide, invasive infection, multiplex
PCR, serotype, Streptococcus pneumoniae
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Streptococcus pneumoniae causes severe illnesses in the
elderly and children. The immunochemistry of the capsular
polysaccharide differentiates pneumococci into 91 distinct
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